# Divergent Strategy for the Diastereoselective Synthesis of the Tricyclic 6,7-Diaryltetrahydro-6*H*-benzo[*c*]chromene Core via Pt(IV)-Catalyzed Cycloaddition of *o*-Quinone Methides and Olefin Ring-Closing Metathesis

Kassrin Tangdenpaisal,<sup>†,‡</sup> Kanokpish Chuayboonsong,<sup>§</sup> Somsak Ruchirawat,<sup>†,‡,§,||</sup> and Poonsakdi Ploypradith<sup>\*,†,‡,§,||</sup>

<sup>†</sup>Laboratory of Medicinal Chemistry, Chulabhorn Research Institute, 54 Kamphaeng Phet 6 Road, Laksi, Bangkok, Thailand 10210 <sup>‡</sup>Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhon Pathom, Thailand 73170

<sup>§</sup>Program in Chemical Biology, Chulabhorn Graduate Institute, 54 Kamphaeng Phet 6 Road, Laksi, Bangkok, Thailand 10210 <sup>||</sup>Centre of Excellence on Environmental Health and Toxicology, Commission on Higher Education (CHE), Ministry of Education, Bangkok, Thailand

**Supporting Information** 



**ABSTRACT:** A divergent strategy for the synthesis of the tricyclic 6,7-diaryltetrahydro-6*H*-benzo[*c*]chromene core was successfully developed. The 2,3-trans, 2,4-cis trisubstituted chroman moiety was formed via highly efficient and stereoselective Pt(IV)-catalyzed cycloaddition reactions of the corresponding quinone methides with chalcones. Subsequent steps provided the common diene alcohol, which underwent  $BF_3$ ·Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction and olefin ring-closing metathesis (RCM) using Ru(II) catalysts. The sequence of the final two steps provided a handle to diversify the stereochemical outcomes at C6 as well as C10a.

# INTRODUCTION

The tricyclic tetrahydro- and hexahydro-6*H*-benzo[*c*]chromenes are the cores of naturally occurring as well as synthetic compounds, many of which display a wide range of interesting and important biological activities.<sup>1-9</sup> Palodesangrens, a group of natural Diels–Alder products isolated from *Brosimum rubescens* Taubert, possess the common tetracyclic tetrahydrobenzo[*c*]pyranochromenone **1**, which also features a unique tricyclic tetrahydro-6*H*-benzo[*c*]chromene core structure with two aryl substituents at C6 and C7 (**2**, Figure 1).<sup>10</sup> Although several elegant approaches have been successfully developed for the total synthesis of some tetrahydro- as well as hexahydro-6*H*-benzo[*c*]chromenes such as (+)-machaeriol A (**3**), (+)-machaeriol B (**4**),<sup>11</sup> (-)-nabilone (**5**),<sup>12</sup> (+)-conicol (**6**),<sup>13</sup> and  $\Delta^9$ -*cis*- and  $\Delta^9$ -*trans*-tetrahydrocannabinols ( $\Delta^9$ -THC, 7**a**,**b**),<sup>14</sup> among others,<sup>15</sup> those toward the synthesis of the more complex tricyclic core of palodesangrens with four contiguous stereocenters at C6, C6a, C7, and C10a, to the best of our knowledge, have never been reported.

The tricyclic core 2 can be considered as a 3,4-cyclohexenylfused chroman derivable from a 3,4-functionalized chroman. In recent years, we have investigated and reported the use of *p*toluenesulfonic acid immobilized on silica (PTS-Si) as well as PtCl<sub>4</sub> as the mediator/catalyst for the generation and [4 + 2] cycloaddition reactions of *o*-quinone methides (*o*-QMs) to prepare functionalized chromans and others.<sup>16</sup> Herein we report, for the first time, the stereoselective synthesis of the 6,7-diaryltetrahydro-6*H*-benzo[*c*]chromene structurally related to the tricyclic core of palodesangrens.

# RESULTS AND DISCUSSION

Initially, we first considered the simplified tricyclic compound 8, where the substituent at C9 was a hydrogen atom instead of a methyl group. In addition, to facilitate the quinone methide chemistry, a methoxy group was placed at C3 while bromine was present at C2.<sup>16</sup> Thus, our approach toward the synthesis of 8 where both Ar groups at C6 and C7 were 4-methoxyphenyl can be outlined retrosynthetically as shown in Scheme 1. While it is plausible to form 8 via an intramolecular [4 + 2] cycloaddition reaction of the diacetate precursor 9, the aldol condensation between benzaldehyde 10 and ketone 11 failed. The presence of an Ar group at the allylic position of 11 renders the proton at that position more acidic; the preformed

Received: December 28, 2016 Published: February 10, 2017



Figure 1. General structures of palodesangrens (1), the tricyclic core 2, and some natural and synthetic tricyclic tetrahydro- as well as hexahydro-6H-benzo[c]chromenes 3–7.

Scheme 1. Retrosynthetic Analysis of the Simplified Tricyclic Compound 8



enolate of **11** under basic conditions may be quenched by this proton, presumably via proton transfer.<sup>17</sup> Thus, the intermolecular [4 + 2] cycloaddition reaction was considered as a means to install the requisite 2,3-*trans* 2,4-*cis* chroman core of **8**. The olefin moiety of the cyclohexenyl ring of **8** could arise from the diene **12** via ring-closing metathesis (RCM).<sup>18</sup> The allyl group of the diene **12** could be installed by allylation followed by reduction (or vice versa) of the ketone functional group in **13**. As the quinone methide precursor, the corresponding benzyl acetates **14** and **15** could be prepared

benzyl acetate **15** in hand, its [4 + 2] cycloaddition reactions with styrene and 4-vinylanisole were carried out using PTS-Si; moderate yields (42–44%) of the desired chromans **20** and **21** were obtained, each as a mixture of inseparable 2,4-cis and 2,4trans diastereomers.<sup>22</sup> The corresponding ketone chroman **22** from a similar reaction using (*E*)-chalcone under PtCl<sub>4</sub> catalysis was also produced, presumably in low yield, as evidenced by the <sup>1</sup>H NMR of the semipurified product.<sup>23</sup> Nevertheless, the results suggested that the PtCl<sub>4</sub>-catalyzed [4 + 2] cycloaddition

Formation of Chroman. The acetate 14, prepared in two steps from 10, was first considered as the quinone methide precursor to prepare 8 (Scheme 2). However, 14 did not

#### Scheme 2. Attempted Synthesis of the Chromans 17 and 19



provide the corresponding product 17 from the anticipated [4 + 2] cycloaddition reactions with simple styrene; decomposition of 14 as well as the allylic alcohol (the intermediate prior to acetylation) was observed under both PTS-Si and PtCl<sub>4</sub> conditions.<sup>19</sup> Similarly, the [4 + 2] cycloaddition reactions of 14 with the diene  $18^{20}$  did not proceed to furnish the desired 2,3,4-trisubstituted chroman 19.

Due to the apparently low stability of 14 under the PTS-Si/ PtCl<sub>4</sub>-mediated [4 + 2] cycloaddition reaction conditions, the benzyl acetate 15 bearing a TMS-protected acetylene moiety as a masked vinyl group<sup>21</sup> was then considered. The benzyl acetate 15 was prepared in a straightforward manner from the aldehyde 10 via TMS acetylide addition followed by acetylation in quantitative yield over two steps (Scheme 3). With the





Table 1.  $PtCl_4$ -Catalyzed [4 + 2] Cycloaddition Reactions between Benzyl Acetate 15 and Various Chalcones  $23a-l^{a}$ 



reaction between the benzyl acetate **15** as a quinone methide precursor and a chalcone as a dienophile was feasible. After some experimentation, upon reaction with chalcone **23a** containing a 4-methoxy substituent on each aromatic ring, the benzyl acetate **15** gave the corresponding ketone chroman **24a** in 85% yield as an inseparable 8:1 mixture of 2,4-cis and 2,4-trans diastereomers.<sup>22</sup> Presumably, the ratio of 2,4-cis to 2,4-trans reflected the endo preference at the transition state of the [4 + 2] cycloaddition.<sup>16</sup>

The scope of the [4 + 2] cycloaddition reactions between the benzyl acetate 15 and various substituted chalcones 23a-1 was investigated. Chalcones 23a-1 with different numbers and substitution patterns of the methoxy group were used; the results are summarized in Table 1.

Moderate to excellent yields (up to 98%) and C2–C4 diastereoselectivity favoring the cis form (5:1 to >99:1) could be obtained from these [4 + 2] cycloaddition reactions. In general, chalcones containing 4-methoxyphenyl group(s) gave good yields and C2–C4 diastereoselectivity for each series (entries 1, 4, 7, and 10). Those chalcones containing 3,4,5-trimethoxyphenyl group(s) as Ar<sup>1</sup>, on the other hand, gave lower yields (38–53%, entries 3, 6, 9, and 12) and C2–C4 diastereoselectivity (5:1). It should be noted that chalcones containing 3,5-dimethoxyphenyl group(s), as either Ar<sup>1</sup> or Ar<sup>2</sup>, did not appreciably undergo the [4 + 2] cycloaddition reactions (<12%).<sup>24</sup> Due to the better yields, the ketone chromans **24a,e,g,h** were chosen for the subsequent steps.

**Installation of the Diene.** With chroman 24a in hand, we then investigated a sequence of (1) desilylation of the TMS group, (2) Lindlar hydrogenation of the terminal alkyne to the corresponding olefin, and (3) allylation of the ketone (or alcohol/acetate) moiety via a Hosomi–Sakurai-type reaction. Cleavage of the TMS group on the TMS-acetylene moiety using *n*-Bu<sub>4</sub>NF (TBAF) led to a product from the chroman ring opening. Thus, the ketone was first reduced using DIBAL-H to the alcohol, which was acetylated under standard conditions to give the acetate 25 in 93% yield over two steps as a single diastereomer (Scheme 4).<sup>25</sup> Stereoselectivity of the DIBAL-H reduction could be accounted for by the approach of the reagent, presumably from the less hindered side of the ketone,

Scheme 4. Attempted Synthesis of the Diene 27



as shown in A. Subsequent TBAF-mediated desilylation followed by hydrogenation of the terminal acetylene using Lindlar's catalyst produced the corresponding olefin 26 in 89% yield over two steps. However, allylation of 26 or its *N*-tosylated amine, under various conditions, did not proceed to give the desired diene 27.<sup>20,26</sup>

At this point, allylation of the ketone via allyl Grignard followed by reduction of the corresponding tertiary alcohol using Et<sub>3</sub>SiH was considered as an alternative to provide the diene **27**. After some experimentation, it was found that desilylation of **24a** could be smoothly affected by  $Cs_2CO_3$  in methanol<sup>27</sup> to furnish the corresponding ketone alkyne **28** in 91% yield as a single diastereomer (Scheme 5). Isomerization at C4 of the minor diastereomer may occur concomitantly under these basic conditions. Hydrogenation of **28** with Lindlar's catalyst at 300 psi of hydrogen gas<sup>28</sup> using a Paar apparatus provided the ketone olefin, which was then treated with allyl Grignard in a diethyl ether (Et<sub>2</sub>O):THF (2:1) solvent mixture to provide the diene alcohol **29** in 82% yield over two steps as a 2:1 inseparable mixture of two diastereomers.<sup>29</sup> Reduction of





the hydroxy group of the diene alcohol **29** could be effectively performed by using  $Et_3SiH$  in the presence of  $BF_3 \cdot Et_2O^{30,31}$  to furnish the desired diene **27** in 86% yield as a single diastereomer, presumably via the transition state **B**, which delivered the hydride from  $Et_3SiH$  syn to the C6a proton.

Ring-Closing Metathesis. With the diene 27 in hand, we next performed the RCM using the second-generation Grubbs ruthenium catalyst. After some experimentation, it was found that RCM of the diene 27 could be best carried out in toluene at 60 °C for 18 h, giving the desired tricyclic compound 30 in 79% yield as a single diastereomer. Surprisingly, from careful NMR analysis of 30, the unanticipated epimerization at the 6position of the tetrahydro-6*H*-benzo [c] chromene (C2 of the chroman) took place under the RCM reaction conditions (Scheme 6).<sup>25</sup> Addition of 1,4-benzoquinone to suppress isomerization under the RCM conditions did not improve the outcome of the reactions.<sup>32</sup> Thus, as an alternative, the sequence of alcohol reduction by Et<sub>3</sub>SiH and RCM was investigated. When the diene alcohol 29 was subjected to the RCM conditions, a separable diastereomeric mixture of the tricyclic alcohols 31 and 32 was obtained in 29% and 48% vields, respectively.<sup>33</sup> The alcohol **31** (7 $\beta$ -OH) then underwent BF<sub>3</sub>·Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction to provide the tricyclic product  $33^{25}$  (H<sub>10aa</sub>) as a single diastereomer in 58% yield. Interestingly, when the alcohol 32 (7 $\alpha$ -OH) underwent such reduction, a separable mixture of 33 and  $34^{25}$  (H<sub>10ab</sub>) was obtained in 18% and 38% yields, respectively. It should be noted that, under the reaction conditions, 34 was formed as a result of reduction at C7 as well as epimerization at C10a. This BF3·Et2O-mediated Et3SiH reduction at C7 for both alcohols 31 and 32 was stereoselective, presumably due to the presence of the more rigid cyclohexenyl ring fused with the chroman system (transition state C), resulting in the delivery of the hydride syn to the C6a proton on the adjacent carbon. Thus, the sequence of BF<sub>3</sub>·Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction and RCM of the diene alcohol 29 serves as a handle to provide differently stereodefined tricyclic products. In other words, generation of a specific diastereomer of the desired tricyclic product (30, 33, and 34) from the common diene alcohol 29 is under the reaction sequence control.

**Scope of the Strategy.** The developed strategy was then applied to the synthesis of other 6,7-diaryltetrahydro-6*H*-benzo[*c*]chromenes from the corresponding chromans **24e**,**g**,**h** 



Scheme 6. Synthesis of the Tricyclic 6,7-Diaryltetrahydro-

(Scheme 7). With the exception of the diene 37a from the reduction of the diene alcohol 36a (3-OMePh as the  $Ar^2$ ), the other corresponding intermediates 35a-c, 36a-c, 37b,c, 39ac, and 40a-c could be prepared in moderate to excellent yields en route to the desired tricyclic compounds 38b,c, 41b,c, and 42a-c (Table 2).<sup>34</sup> It should be noted that the BF<sub>3</sub>·Et<sub>2</sub>Omediated Et<sub>3</sub>SiH reduction of **36a** (Ar<sup>1</sup> = 3,4-(OMe)<sub>2</sub>Ph; Ar<sup>2</sup> = 3-OMePh) gave no desired product 37a; only a mixture of unidentifiable compounds could be obtained. Hence, without 37a, the subsequent Grubbs II RCM could not be performed to vield the tricyclic product 38a. In addition, when the tricyclic alcohol 39a underwent the BF<sub>3</sub>·Et<sub>2</sub>O-mediated Et<sub>2</sub>SiH reduction, the expected tricyclic product 41a was not obtained. The tricyclic compound 42a, with concomitant 10a-isomerization, was produced from the reaction instead. Interestingly, when 40a was subjected to this reduction, 42a, one of the expected products, was obtained in low yield (15%) along with the nonreduced product with 10a,6a-isomerization  $43^{35}$  (Figure 2) in 19% yield. Interestingly, when 40c ( $Ar^1 = Ar^2 = 3,4$ -(OMe)<sub>2</sub>Ph) underwent the BF<sub>3</sub>·Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction, only the tricyclic product 42c with 10a-isomerization was obtained; no 41c was observed.

Lindlar hydrogenation followed by methallylation of the ketone alkyne **28** could install the requisite methyl group at C9 and furnish the corresponding alcohol **44** in 75% yield over two steps. After some experimentation, subsequent RCM of **44** using Grubbs II catalyst under various conditions proceeded more sluggishly than those of other similar dienes (**29**, **37b**,*c*, **39a**-*c*, and **40a**-*c*) to give a separable mixture of the corresponding tricyclic alcohols **45** (7 $\beta$ -OH) and **46** (7 $\alpha$ -OH) in 26% and 30% yields, respectively.<sup>34</sup> When the catalyst was changed to Hoveyda–Grubbs II, better yields of both **45** (35%) and **46** (38%) could be obtained. In the final step, hydride reduction of the alcohol **45** furnished the desired

Scheme 7. Scope of the Developed Chemistry to Prepare Diverse Tricyclic 6,7-Diaryltetrahydro-6*H*-benzo[c]chromenes 38b,c, 41b,c, 42a-c, and 47



Table 2. Scope of the Currently Developed Strategy

entry	TMS alkyne	ketone alkyne <sup>a</sup>	diene alcohol <sup>a</sup>	diene <sup>a</sup>	tricyclic product <sup>a</sup>	tricyclic alcohols <sup>a</sup>	tricyclic products <sup>a</sup>
1	24e	35a (86)	36a (98)	37a (0)	<b>38a</b> (0)	<b>39a</b> (26)	<b>42a</b> (19)
						<b>40a</b> (65)	<b>42a</b> (15), <b>43</b> <sup>b</sup>
2	24g	35b (97)	36b (90)	37b (54)	<b>38b</b> (81)	<b>39b</b> (23)	<b>41b</b> (50, 18) <sup>c</sup>
						<b>40b</b> (50)	<b>42b</b> (27)
3	24h	35c (88)	36c (93)	37c (34)	<b>38c</b> (80)	<b>39c</b> (34)	<b>41c</b> (67)
						<b>40</b> c (60)	<b>42c</b> (37)

<sup>*a*</sup>Values in parentheses are the isolated yields. <sup>*b*</sup>19% of **43** was obtained. <sup>*c*</sup>The first value refers to the yield from **39b**, while the second value refers to the yield from **40b**.



Figure 2. Nonreduced tricyclic product 43, diene 49, and tricyclic product 50.

product 47 ( $H_{10a\alpha}$ ) in 84% yield as a single isomer while the alcohol 46 furnished a separable mixture of 47 and the nonreduced 10a,6a-isomerized tricyclic alcohol 48<sup>35</sup> ( $H_{10a\beta}$ ) in 35% and 22% yields, respectively. It should be noted that, while 44 could undergo the hydride reduction to give the corresponding diene 49, its subsequent RCM, under various

RCM conditions, did not proceed to furnish the corresponding tricyclic product **50**.

## CONCLUSION

A synthetic approach for the tricyclic 6,7-diaryltetrahydro-6Hbenzo[*c*]chromenes has been successfully developed employing simple benzaldehydes and acetophenones as building blocks. The skeleton of the tricyclic system comprises two units of benzaldehyde derivatives (one as the chroman aromatic ring and the other as the aryl group  $(Ar^1)$  on C6), one unit of acetophenone (as the aryl group  $(Ar^2)$  on C7), and one threecarbon (allylic) unit (as part of the cyclohexene ring). The chroman moiety was assembled first via a highly efficient and stereoselective [4 + 2] cycloaddition reaction between the *o*-QMs derived from the TMS-protected acetylene benzyl acetate and chalcones. Subsequent reactions on the TMS-protected alkyne group converted such a moiety to the corresponding olefin. The requisite allylic moiety was then added to the ketone via the Grignard reaction. The sequence of the remaining two steps of Grubbs RCM and BF3·Et2O-mediated Et<sub>3</sub>SiH reduction on the resulting diene alcohol could be exploited to provide the final different tricyclic products in a stereodefined manner. Thus, through eight steps starting from the benzaldehyde building block 10, the desired complex

tricyclic 6,7-diaryltetrahydro-6*H*-benzo[c]chromenes containing four contiguous stereocenters could be obtained in good overall yields (up to 43%). Applications of the developed method have been further investigated for the total synthesis of palodesangrens, and the results will be reported in due course.

## EXPERIMENTAL SECTION

General Experimental Methods. Unless otherwise noted. reactions were run in oven-dried round-bottomed flasks. Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl or purified by the solvent purification system, while dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>) was also purified by the solvent purification system prior to use. All other compounds were used as received from the suppliers; PTS-Si (p-TsOH immobilized on silica) employed in these experiments possessed a surface area of 500  $m^2/g$ , as indicated by the supplier. The crude reaction mixtures were concentrated under reduced pressure by removing organic solvents on a rotary evaporator. Column chromatography was performed using silica gel 60 (particle size 0.06-0.2 mm; 70-230 mesh ASTM). Analytical thin-layer chromatography (TLC) was performed with silica gel 60  $F_{254}$ aluminum sheets. Chemical shifts for <sup>1</sup>H nuclear magnetic resonance (NMR) spectra are reported in parts per million (ppm,  $\delta$ ) downfield from tetramethylsilane. Splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), broad (br), doublet of doublets (dd), doublet of triplets (dt), and doublet of doublets of doublets (ddd). Resonances for infrared (IR) spectra are reported in wavenumbers (cm<sup>-1</sup>). Low-resolution (LRMS) mass spectra were obtained using either electron ionization (EI) or time of flight (TOF), while high-resolution (HRMS) mass spectra were obtained using TOF via atmospheric-pressure chemical ionization (APCI) or electrospray ionization (ESI). Melting points are uncorrected.

**1-(5-Bromo-4-methoxy-2-(methoxymethoxy)phenyl)allyl Acetate (14).** Allylmagnesium chloride (1.6 M in THF, 0.33 mL, 0.52 mmol) was added to a solution of benzaldehyde **10** (0.110 g, 0.40 mmol) in THF (2 mL) at 0 °C. The reaction mixture was stirred for 4 h and then was quenched with saturated NH<sub>4</sub>Cl (2 mL). The resulting mixture was extracted with EtOAc ( $3 \times 2$  mL), and the combined organic layers were washed with water ( $3 \times 2$  mL) and brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and filtered. The filtrate was evaporated (aspirator then vacuum) to give a crude product, which was used in the next step without further purification.

A solution of the benzyl alcohol and N,N-dimethylaminopyridine (DMAP; 0.073 g, 0.6 mmol) in dichloromethane (DCM; 2 mL) was cooled in an ice bath for 10 min before Et<sub>3</sub>N (0.08 mL, 0.6 mmol) and Ac<sub>2</sub>O (0.06 mL, 0.6 mmol) were added successively. The mixture was warmed to room temperature, at which it was stirred for 2 h. The reaction mixture was quenched with water (2 mL), the resulting mixture was extracted with DCM ( $3 \times 2$  mL), and the combined organic phases were washed with water  $(3 \times 2 \text{ mL})$  and brine (2 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a crude product, which was purified by column chromatography on silica (15-20% EtOAc/hexanes) to give the desired product 14 as a colorless oil (0.125 g, 0.36 mmol, 90% over two steps). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.11 (s, 3H), 3.48 (s, 3H), 3.88 (s, 3H), 5.205 (dt, J = 10.4, 1.3 Hz, 1H), 5.207 (s, 2H), 5.23 (dt, J = 17.1, 1.3 Hz, 1H), 5.97 (ddd, J = 17.1, 10.4, 5.5 Hz, 1H), 6.58 (dt, J = 5.5, 1.3 Hz, 1H), 6.74 (s, 1H), 7.47 (s, 1H).  $^{13}\mathrm{C}$  NMR (75 MHz, CDCl<sub>2</sub>):  $\delta$ 21.1, 56.1, 56.3, 69.8, 94.7, 99.6, 103.4, 116.2, 121.7, 131.6, 135.6, 154.6, 156.3, 167.7. TOF-HRMS: calcd for  $C_{14}H_{17}^{-9}BrNaO_5$  (M + Na<sup>+</sup>) 367.0152, found 367.0147; calcd for  $C_{14}H_{17}^{-81}BrNaO_5$  (M + Na<sup>+</sup>) 369.0133. found 369.0133.

**1-(5-Bromo-4-methoxy-2-(methoxymethoxy)phenyl)-3-**(trimethylsilyl)prop-2-yn-1-yl Acetate (15). To a solution of ethynyltrimethylsilane (3.50 mL, 24.0 mmol) in THF (20 mL) was slowly added *n*-BuLi (1.55 M, 12.9 mL, 20 mmol) at -78 °C. The mixture was then warmed to 0 °C, at which it was stirred for 2 h. A solution of benzaldehyde **10** (2.20 g, 8.00 mmol) in THF (20 mL) was added to the TMS acetylide solution at 0 °C. The mixture was warmed to room temperature, and the reaction mixture was stirred for 18 h. The resulting mixture was quenched with saturated NH<sub>4</sub>Cl (20 mL). The aqueous layer was extracted with EtOAc ( $3 \times 20$  mL), and the combined organic phases were washed with water ( $3 \times 20$  mL) and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a crude product which was used in the next step without further purification.

A solution of the benzyl alcohol and DMAP (1.50 g, 12.0 mmol) in DCM (40 mL) was cooled in an ice bath for 10 min before Et<sub>3</sub>N (1.70 mL, 12.0 mmol) and Ac<sub>2</sub>O (1.20 mL, 12.0 mmol) were added successively. The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water (10 mL), and the resulting mixture was extracted with DCM ( $3 \times 20$  mL). The combined organic phases were washed with water  $(3 \times 20 \text{ mL})$  and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a crude product which was purified by column chromatography on silica (15-20% EtOAc/hexanes) to give the desired product 15 as a white solid (3.31 g, 8.00 mmol, 100% over two steps). Mp (EtOAc/ hexanes):: 79.4-80.2 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.20 (s, 9H), 2.08 (s, 3H), 3.48 (s, 3H), 3.89 (s, 3H), 5.20 (br s, 2H), 6.71 (s, 1H), 6.74 (s, 1H), 7.79 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ -0.28, 21.0, 56.2, 56.4, 60.1, 92.0, 94.7, 99.4, 101.1, 103.4, 119.5, 133.0, 154.9, 157.2, 169.4. IR (UATR):  $\nu_{\rm max}$  2960, 2180, 1743, 1218, 843 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 416 (1.45)  $[C_{17}H_{23}^{81}BrO_5Si]^+$ , 414 (1.16)  $[C_{17}H_{23}^{79}BrO_5Si]^+$ , 312 (92), 310 (87), 73 (100). TOF-HRMS: calcd for  $C_{17}H_{23}^{79}$ BrNaO<sub>5</sub>Si (M + Na<sup>+</sup>) 437.0390, found 437.0379; calcd for  $C_{17}H_{23}^{81}$ BrNaO<sub>5</sub>Si (M + Na<sup>+</sup>) 439.0372, found 439.0366.

General Procedure for the PTS-Si-Mediated Generation of *o*-QM and the [4 + 2] Cycloaddition Reaction. To a stirred solution of benzyl acetate 15 (1.0 equiv) in toluene (5 mL/mmol) was added the corresponding styrene (10 equiv) or its derivative (2 equiv in the case of 4-methoxystyrene) at room temperature. The resulting mixture was stirred at 0 °C for 10 min, and then PTS-Si (1.1 equiv) was added. The mixture was then slowly warmed to room temperature. The reaction mixture was stirred until the starting material was consumed, as indicated by TLC (typically 1–4 h). At that time, PTS-Si was filtered off and the resulting mixture was concentrated under reduced pressure to give a crude product mixture which was further purified by PTLC (10% EtOAc/hexanes) to furnish the desired product.

((6-Bromo-7-methoxy-2-phenylchroman-4-yl)ethynyl)trimethylsilane (20). Following the general procedure for the PTS-Si-mediated o-QM/[4 + 2] cycloaddition reaction, benzyl acetate 15 (0.029 g, 0.070 mmol) furnished the chroman product 20 as an 8:1 (2,4-cis:2,4-trans) inseparable mixture of diastereomers as a colorless oil (0.012 g, 0.029 mmol, 42%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  0.17 (s, 9H, minor), 0.18 (s, 9H, major), 2.17 (dt, J = 13.7, 11.8 Hz, 1H, major), 2.21–2.28 (m, 2H, minor), 2.46 (ddd, J = 13.7, 5.3, 1.9, 1H, major), 3.74 (t, J = 4.5 Hz, 1H, minor), 3.83 (s, 3H, major), 3.84 (s, 3H, minor), 4.07 (ddd, J = 11.8, 5.3, 0.9 Hz, 1H, major), 5.00 (dd, J = 11.8, 1.9 Hz, 1H, major), 5.34 (dd, J = 9.0, 3.0, 1H, minor), 6.46 (s, 1H), 6.51 (s, 1H, minor), 7.31–7.45 (m, 5H), 7.66 (d, J = 0.9 Hz, 1H, major). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 0.0 (major), 0.1 (minor), 27.0 (minor), 29.3 (major), 35.6 (minor), 36.8 (major), 56.2 (minor), 56.3 (major), 75.0 (minor), 78.0 (major), 86.9 (major), 100.9 (major), 101.1 (minor), 102.6 (major), 106.3 (major), 107.9 (minor), 114.7 (major), 125.9 (minor), 126.1 (major), 128.1 (minor), 128.4 (major), 128.7 (major), 132.7 (major), 133.3 (minor), 140.2 (major), 140.5 (minor), 154.2 (minor), 154.3 (major), 155.8 (major). TOF-HRMS: calcd for  $C_{21}H_{23}^{79}BrNaO_2Si (M + Na^+) 437.0543$ , found 437.0537; calcd for  $C_{21}H_{23}^{81}BrO_2Si (M + Na^+) 439.0525$ , found 439.0519.

((6-Bromo-7-methoxy-2-(4-methoxyphenyl)chroman-4-yl)ethynyl)trimethylsilane (21). Following the general procedure for the PTS-Si-mediated o-QM/[4 + 2] cycloaddition reaction, benzyl acetate 15 (0.042 g, 0.100 mmol) furnished the chroman product 21 as a 2:1 (2,4-*cis*:2,4-*trans*) inseparable mixture of diastereomers as a colorless oil (0.019 g, 0.044 mmol, 44%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  0.17 (s, 9H, minor), 0.19 (s, 9H, major), 2.18–2.26 (m, 2H, minor), 2.19 (dt, J = 13.7, 11.8 Hz, 1H, major), 2.42 (ddd, J =13.7, 5.4, 1.9 Hz, 1H, major), 3.75 (t, J = 4.4 Hz, 1H, minor), 3.82 (s, 3H), 3.83 (s, 3H, major), 3.84 (s, 3H, minor), 4.06 (ddd, J = 11.8, 5.4, 1.0 Hz, 1H, major), 4.95 (dd, J = 11.8, 1.9, 1H, major), 5.29 (dd, J = 8.4, 3.8 Hz, 1H, minor), 6.44 (s, 1H, major), 6.49 (s, 1H, minor), 6.93 (d, J = 8.6 Hz, 2H), 7.33 (d, J = 8.6 Hz, 2H, minor), 7.35 (d, J = 8.6 Hz, 2H, major), 7.43 (s, 1H, minor), 7.65 (d, J = 1.0 Hz, 1H, major). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  0.0 (major), 0.1 (minor), 27.2, (minor), 29.4 (major), 35.4 (minor), 36.6 (major), 55.3, 56.2 (minor), 56.3 (major), 74.7 (minor), 102.4 (minor), 102.5 (major), 106.4 (major), 108.0 (minor), 114.1, 114.7 (major), 114.8 (minor), 127.4 (minor), 127.5 (major), 132.3 (major), 132.6 (minor), 132.7 (major), 133.3 (minor), 154.3 (minor), 154.4 (major), 155.7, 159.5 (minor), 159.7 (major). TOF-HRMS: calcd for C<sub>22</sub>H<sub>25</sub><sup>79</sup>BrNaO<sub>3</sub>Si (M + Na<sup>+</sup>) 467.0649, found 467.0638; calcd for C<sub>22</sub>H<sub>25</sub><sup>81</sup>BrNaO<sub>3</sub>Si (M + Na<sup>+</sup>) 469.0631, found 469.0622.

General Procedure for the PtCl<sub>4</sub>-Catalyzed Generation of *o*-QM and the [4 + 2] Cycloaddition Reaction with Chalcones 23a–I. To a stirred solution of benzyl acetate 15 (1.0 equiv) in DCM (10 mL/mmol) was added chalcone 23a–I (2 equiv) at room temperature. The resulting mixture was stirred at 0 °C for 10 min, and then PtCl<sub>4</sub> (10 mol %) was added. The mixture was then slowly warmed to room temperature. The reaction mixture was stirred until the starting material was consumed, as indicated by TLC (typically 2–4 h). At that time, the reaction mixture was concentrated under reduced pressure to give a crude product mixture which was further purified by PTLC (20–40% EtOAc/hexanes) to furnish the desired products 24a-I.

(6-Bromo-7-methoxy-2-(4-methoxyphenyl)-4-((trimethylsilyl)ethynyl)chroman-3-yl)(4-methoxyphenyl)methanone (24a). Following the general procedure for the PtCl<sub>4</sub>catalyzed o-QM/[4 + 2] cycloaddition reaction using chalcone 23a, benzyl acetate 15 (0.200 g, 0.482 mmol) furnished the corresponding chroman 24a as a 8:1 (2,4-cis:2,4-trans) inseparable mixture of diastereomers as a yellow sticky gum (0.237 g, 0.410 mmol, 85%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ -0.07 (s, 9H, major), 0.11 (s, 9H, minor), 3.69 (s, 3H, major), 3.76 (s, 3H, minor), 3.80 (s, 3H, major), 3.82 (s, 3H, minor), 3.83 (s, 3H, major), 3.84 (s, 3H, minor), 4.11 (dd, J = 11.0, 10.0 Hz, 1H, major), 4.38 (dd, J = 11.0, 0.9 Hz, 1H, major), 5.12 (d, I = 10.0 Hz, 1H, major), 5.56 (d, I = 9.1 Hz, 1H, minor), 6.49 (s, 1H, major), 6.50 (s, 1H, minor), 6.73 (d, J = 8.7 Hz, 2H, major), 6.76 (d, J = 8.9 Hz, 2H, major), 6.86 (d, J = 8.7 Hz, 2H, minor), 6.91 (d, J = 8.9 Hz, 2H, minor), 7.26 (d, J = 8.7 Hz, 2H, major), 7.398 (d, J = 8.7 Hz, 2H, minor), 7.400 (s, 1H, minor), 7.69 (d, J = 0.9 Hz, 1H, major), 7.81 (d, J = 8.9 Hz, 2H, major), 7.83 (d, J = 8.9 Hz, 2H, minor). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ –0.4 (major), –0.2 (minor), 31.8 (minor), 33.9 (major), 48.2 (minor), 50.7 (major), 55.1 (major), 55.2 (minor), 55.4 (major), 55.5 (minor), 56.2 (minor), 56.3 (major), 76.1 (minor), 80.0 (major), 89.1 (major), 100.7 (major), 100.9 (minor), 102.5 (minor), 102.8 (major), 103.2 (minor), 104.0 (major), 113.4 (major), 113.85 (major), 113.90 (minor), 113.95 (minor), 114.1 (minor), 114.4 (major), 128.5 (major), 128.8 (minor), 129.4 (minor), 129.7 (major), 130.1 (minor), 130.2, (minor), 130.8 (major), 131.0 (major), 131.4 (minor), 132.5 (minor), 132.8 (major), 153.8 (major), 155.8 (major), 159.5 (minor), 159.7 (major), 163.6 (major), 194.2 (minor), 198.9 (major). IR (UATR):  $\nu_{\rm max}$  2959, 2838, 2175, 1666, 1600, 1249, 839 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 580 (19)  $[C_{30}H_{31}^{81}BrO_5Si]^+$ , 578 (17)  $[C_{30}H_{31}^{79}BrO_5Si]^+$ , 268 (21), 135 (100). TOF-HRMS: calcd for  $C_{30}H_{32}^{79}BrO_5Si$  (M + H<sup>+</sup>) 579.1197, found 579.1180; calcd for  $C_{30}H_{32}^{81}BrO_5Si$  (M + H<sup>+</sup>) 581.1182, found 581.1144

(6-Bromo-2-(3,4-dimethoxyphenyl)-7-methoxy-4-((trimethylsilyl)ethynyl)chroman-3-yl)(4-methoxyphenyl)methanone (24b). Following the general procedure for the PtCl<sub>4</sub>catalyzed *o*-QM/[4 + 2] cycloaddition reaction using chalcone 23b, benzyl acetate 15 (0.021 g, 0.050 mmol) furnished chroman 24b as a 8:1 (2,4-*cis*:2,4-*trans*) inseparable mixture of diastereomers as a yellow solid (0.017 g, 0.028 mmol, 56%). Mp (EtOAc/hexanes): 74.5–76.6 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  –0.06 (s, 9H, major), 0.11 (s, 9H, minor), 3.768 (s, 3H, major), 3.774 (s, 3H, major), 3.81 (s, 3H, major), 3.83 (s, 3H, minor), 3.84 (s, 3H, major), 3.856 (s, 3H, minor), 3.862 (s, 3H, minor), 4.14 (dd, *J* = 11.0, 10.0 Hz, 1H, major), 4.39

(dd, J = 11.0, 1.0, 1H, major), 5.11 (d, J = 10.0, 1H, major), 5.55 (d, J = 9.2 Hz, 1H, minor), 6.51, (s, 1H, major), 6.52 (s, 1H, minor), 6.70 (d, J = 8.2 Hz, 1H, major), 6.79 (d, J = 8.9 Hz, 2H, major), 6.84 (d, J = 1.9 Hz, 1H, major), 6.89 (dd, J = 8.2, 1.9 Hz, 1H, major), 6.98 (d, J = 2.0 Hz, 1H, minor), 7.04 (dd, J = 8.3, 2.0 Hz, 1H, minor), 7.41 (s, 1H, minor), 7.49 (d, J = 8.3 Hz, 1H, minor), 7.70 (d, J = 1.0 Hz, 1H, major), 7.75 (d, J = 8.9 Hz, 2H, major), 7.84 (d, J = 8.9 Hz, 2H, minor). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  –0.4 (major), –0.2 (minor), 31.8 (minor), 33.9 (major), 48.1 (minor), 50.6 (major), 55.4 (major), 55.5 (minor), 55.79 (major), 55.80 (major), 55.9 (minor), 56.2 (minor), 56.3 (major), 80.2 (major), 89.1 (major), 100.7 (major), 101.0 (minor), 102.9 (major), 104.0 (major), 110.0 (major), 110.9 (major), 111.1 (minor), 113.5 (major), 114.0 (minor), 114.1 (minor), 114.4 (major), 120.2 (major), 129.9 (major), 130.2 (minor), 130.7 (major), 131.0 (major), 132.6 (major), 132.9 (minor), 148.9 (major), 149.2 (major), 153.7 (major), 155.8 (major), 163.7 (major), 198.9 (major). IR (UATR):  $\nu_{max}$  2959, 2835, 2172, 1598, 1259, 1160 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 610 (0.2)  $[C_{31}H_{33}^{81}BrO_6Si]^+$ , 608 (0.2)  $[C_{31}H_{33}^{79}BrO_6Si]^+$ , 195 (100). TOF-HRMS: calcd for C<sub>31</sub>H<sub>33</sub><sup>79</sup>BrNaO<sub>6</sub>Si (M + Na<sup>+</sup>) 631.1120, found 631.1117; calcd for  $C_{31}H_{33}^{-81}$ BrNaO<sub>6</sub>Si (M + Na<sup>+</sup>) 633.1107, found 633.1117.

(6-Bromo-2-(3,4,5-trimethoxyphenyl)-7-methoxy-4-((trimethylsilyl)ethynyl)chroman-3-yl)(4-methoxyphenyl)methanone (24c). Following the general procedure for the PtCl<sub>4</sub>catalyzed o-QM/[4 + 2] cycloaddition reaction using chalcone 23c, benzyl acetate 15 (0.021 g, 0.050 mmol) furnished chroman 24c as a 7:1 (2,4-cis:2,4-trans) inseparable mixture of diastereomers as a yellow sticky gum (0.013 g, 0.021 mmol, 41%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  -0.04 (s, 9H, major), 0.12 (s, 9H, minor), 3.70 (s, 3H, major), 3.74 (s, 6H, major), 3.80 (s, 3H, minor), 3.81 (s, 3H, major), 3.83 (s, 6H, minor), 3.85 (s. 3H, major), 3.86 (s, 3H, minor), 3.94 (s, 3H, minor), 4.13 (dd, J = 11.0, 10.0 Hz, 1H, major), 4.42 (dd, J = 11.0, 1.0 Hz, 1H, major), 5.06 (d, J = 10.0 Hz, 1H, major), 5.53 (d, J = 9.2 Hz, 1H, minor), 6.52 (s, 1H, major), 6.54 (s, 2H, major), 6.68 (s, 2H, minor), 6.79 (d, J = 8.9 Hz, 2H, major), 6.93 (d, J = 8.9, 2H, minor), 7.13 (s, 1H, minor), 7.41 (s, 1H, minor), 7.71 (d, J = 1.0 Hz, 1H, major), 7.74 (d, J = 8.9 Hz, 2H, major), 7.85 (d, J = 8.9 Hz, 2H, minor). <sup>13</sup>C NMR  $(75 \text{ MHz}, \text{CDCl}_{2}): \delta - 0.4 \text{ (major)}, -0.2 \text{ (minor)}, 31.7 \text{ (minor)}, 33.6$ (major), 47.9 (minor), 50.7 (major), 55.4 (major), 55.5 (minor), 56.1 (major), 56.2 (minor), 56.25 (minor), 56.31 (major), 60.65 (major), 60.68 (minor), 76.8 (minor), 80.5 (major), 89.0 (major), 91.4 (minor), 100.7 (major), 100.9 (minor), 103.1 (major), 104.0 (major), 104.5 (major), 104.9 (minor), 106.7 (minor), 113.4 (major), 114.0 (minor), 114.3 (major), 130.2 (minor), 130.6 (major), 131.0 (major), 132.7 (major), 132.8 (major), 134.7 (minor), 138.1 (minor), 153.2 (major), 155.5 (major), 155.8 (major), 156.1 (minor), 163.7 (major), 191.0 (minor), 198.7 (major). IR (UATR):  $\nu_{\rm max}$  2959, 2175, 1664, 1596, 1125 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 641 (19)  $[C_{32}H_{36}^{81}BrO_7Si]^+$ , 639 (20)  $[C_{32}H_{36}^{79}BrO_7Si]^+$ , 328 (26), 135 (100). TOF-HRMS: calcd for  $C_{32}H_{35}^{79}BrNaO_7Si$  (M + Na<sup>+</sup>) 661.1228, found 661.1240; calcd for C<sub>32</sub>H<sub>35</sub><sup>81</sup>BrNaO<sub>7</sub>Si (M + Na<sup>+</sup>) 663.1213, found 663.1232.

(6-Bromo-7-methoxy-2-(4-methoxyphenyl)-4-((trimethylsilyl)ethynyl)chroman-3-yl)(3-methoxyphenyl)**methanone (24d).** Following the general procedure for the PtCl<sub>4</sub>catalyzed o-QM/[4 + 2] cycloaddition reaction using chalcone 23d, benzyl acetate 15 (0.021 g, 0.050 mmol) furnished chroman 24d as a single diastereomer as a white sticky gum (0.018 g, 0.030 mmol, 60%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  –0.05 (s, 9H), 3.72 (s, 3H), 3.78 (s, 3H), 3.86 (s, 3H), 4.15 (dd, J = 11.0, 10.1 Hz, 1H), 4.41 (dd, J = 11.0, 1.1 Hz, 1H), 5.14 (d, J = 10.1 Hz, 1H), 6.52 (s, 1H), 6.76 (d, J = 8.7 Hz, 2H), 7.02 (ddd, J = 8.1, 2.6, 0.9 Hz, 1H), 7.18–7.22 (m, 1H), 7.23–7.30 (m, 3H), 7.31–7.36 (m, 1H), 7.72 (d, J = 1.1 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ -0.5, 34.0, 51.5, 55.2, 55.3, 56.3, 80.0, 89.3, 100.7, 102.9, 103.7, 112.2, 113.9, 114.2, 119.8, 121.2, 128.5, 129.2, 129.5, 132.5, 139.3, 153.7, 155.8, 159.5, 160.0, 200.9. IR (UATR):  $\nu_{\rm max}$  2959, 2837, 2172, 1674, 1488, 1250, 1152  ${\rm cm^{-1}}.$  LRMS (EI): m/z (rel intensity) 580 (1)  $[C_{30}H_{31}^{81}BrO_{5}Si]^{+}$ , 578 (1) [C<sub>30</sub>H<sub>31</sub><sup>79</sup>BrO<sub>5</sub>Si]<sup>+</sup>, 165 (100). TOF-HRMS: calcd for

 $C_{30}H_{31}{}^{79}BrNaO_5Si~(M + Na^+)$  601.1016, found 601.1020; calcd for  $C_{30}H_{31}{}^{81}BrNaO_5Si~(M + Na^+)$  603.1001, found 603.0992.

(6-Bromo-2-(3,4-dimethoxyphenyl)-7-methoxy-4-((trimethylsilyl)ethynyl)chroman-3-yl)(3-methoxyphenyl)methanone (24e). Following the general procedure for the PtCl<sub>4</sub>catalyzed o-QM/[4 + 2] cycloaddition reaction using chalcone 23e, benzyl acetate 15 (0.021 g, 0.050 mmol) furnished chroman 24e as a single diastereomer as a yellow sticky gum (0.021 g, 0.034 mmol, 68%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ –0.06 (s, 9H), 3.76 (s, 6H), 3.78 (s, 3H), 3.84 (s, 3H), 4.17 (dd, J = 11.0, 10.0 Hz, 1H), 4.40 (dd, J = 11.0, 1.0 Hz, 1H), 5.09 (d, J = 10.0 Hz, 1H), 6.51 (s, 1H), 6.71 (d, J = 8.2 Hz, 1H), 6.84 (d, I = 2.0 Hz, 1H), 6.89 (dd, I = 8.2, 2.0 Hz, 1H), 7.01 (ddd, J = 8.1, 2.6, 0.8 Hz, 1H), 7.18 (d, J = 1.6 Hz, 1H), 7.22 (dd, *J* = 8.1, 7.8 Hz, 1H), 7.34 (br d, *J* = 7.8 Hz, 1H), 7.70 (d, *J* = 1.0 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>2</sub>):  $\delta$  -0.5, 33.9, 51.4, 55.3, 55.80, 55.81, 56.3, 80.3, 89.2, 100.7, 103.0, 103.8, 110.0, 110.9, 112.5, 114.2, 121.1, 129.2, 129.7, 132.9, 139.3, 148.9, 149.3, 153.7, 155.9, 159.5, 200.8. IR (UATR):  $\nu_{\rm max}$  2958, 2837, 2176, 1674, 1262, 1151 cm  $^{-1}$ LRMS (EI): m/z (rel intensity) 610 (20)  $[C_{31}H_{33}^{81}BrO_6Si]^+$ , 608 (18) [C<sub>31</sub>H<sub>33</sub><sup>79</sup>BrO<sub>6</sub>Si]<sup>+</sup>, 475 (71), 298 (78), 135 (100). TOF-HRMS: calcd for  $C_{31}H_{33}^{79}BrNaO_6Si (M + Na^+) 631.1122$ , found 631.1103; calcd for  $C_{31}H_{33}^{-81}BrNaO_6Si$  (M + Na<sup>+</sup>) 633.1107, found 633.1112.

(6-Bromo-2-(3,4,5-trimethoxyphenyl)-7-methoxy-4-((trimethylsilyl)ethynyl)chroman-3-yl)(3-methoxyphenyl)methanone (24f). Following the general procedure for the PtCl<sub>4</sub>catalyzed o-QM/[4 + 2] cycloaddition reaction using chalcone 23f, benzyl acetate 15 (0.021 g, 0.050 mmol) furnished chroman 24f as a 6:1 (2,4-cis:2,4-trans) inseparable mixture of diastereomers as a yellow sticky gum (0.014 g, 0.022 mmol, 44%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  -0.04 (s, 9H, major), 0.13 (s, 9H, minor), 3.70 (s, 3H, major), 3.73 (s, 6H, major), 3.76 (s, 3H, major), 3.80 (s, 3H, minor), 3.83 (s, 3H, minor), 3.84 (s, 6H, minor), 3.85 (s, 3H, major), 4.17 (dd, J = 11.0, 10.0 Hz, 1H, major), 4.24 (dd, J = 9.3, 5.3 Hz, 1H, minor), 4.43 (dd, J = 11.0, 1.0 Hz, 1H, major), 5.04 (d, J = 10.0 Hz, 1H, major), 5.52 (d, J = 9.3 Hz, 1H, minor), 6.52 (s, 1H, major), 6.53 (s, 2H, major), 6.69 (s, 2H, minor), 7.01 (ddd, J = 8.1, 2.5, 1.0 Hz, 1H, major), 7.12 (ddd, J = 7.8, 2.6, 1.0 Hz, 1H, minor), 7.14 (s, 1H, minor), 7.17 (dd, J = 2.5, 1.4 Hz, 1H, major), 7.23 (dd, J = 8.1, 7.8 Hz, 1H, major), 7.34 (ddd, J = 7.8, 1.4, 1.0 Hz, 1H, major), 7.34–7.42 (m, 3H, minor), 7.44 (ddd, J = 7.8, 1.3, 1.0 Hz, 1H, minor), 7.71 (d, J = 1.0 Hz, 1H, major). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ -0.4 (major), -0.2 (minor), 31.7 (minor), 33.7 (major), 48.6 (minor), 51.6 (major), 55.3 (major), 55.4 (minor), 56.1 (major), 56.2 (minor), 56.3 (minor), 56.4 (major), 60.70 (major), 60.73 (minor), 80.6 (major), 89.2 (major), 100.8 (major), 101.0 (minor), 102.9 (minor), 103.0 (major), 103.3 (major), 103.8 (major), 104.6 (major), 105.0 (minor), 112.5 (major), 114.0 (minor), 114.2 (major), 119.6 (major), 119.8 (minor), 120.2 (minor), 120.9 (major), 129.2 (major), 129.8 (minor), 132.6 (major), 132.7 (major), 132.9 (minor), 137.9 (minor), 138.4 (minor), 139.5 (major), 153.25 (major), 153.28 (major), 153.5 (major), 153.6 (minor), 155.9 (major), 156.2 (minor), 159.5 (major), 160.2 (minor), 195.6 (minor), 200.6 (major). IR (UATR):  $\nu_{\rm max}$  2957, 2839, 2167, 1657, 1263, 1123, 842 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 640 (24)  $[C_{32}H_{35}^{81}BrO_7Si]^+$ , 638 (21)  $[C_{32}H_{35}^{-7}BrO_7Si]^+$ , 505 (57), 503 (64), 328 (82), 297 (50), 135 (100). TOF-HRMS: calcd for  $C_{32}H_{35}^{79}BrNaO_7Si$  (M + Na<sup>+</sup>) 661.1228, found 661.1234; calcd for  $C_{32}H_{35}^{-81}BrNaO_7Si$  (M + Na<sup>+</sup>) 663.1213, found 663.1203.

(6-Bromo-7-methoxy-2-(4-methoxyphenyl)-4-((trimethylsilyl)ethynyl)chroman-3-yl)(3,4-dimethoxyphenyl)methanone (24g). Following the general procedure for the PtCl<sub>4</sub>catalyzed *o*-QM/[4 + 2] cycloaddition reaction using chalcone 23g, benzyl acetate 15 (0.021 g, 0.050 mmol) furnished chroman 24g as a 8:1 (2,4-*cis*:2,4-*trans*) inseparable mixture of diastereomers as a yellow sticky gum (0.030 g, 0.049 mmol, 98%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  -0.07 (s, 9H, major), 0.12 (s, 9H, minor), 3.70 (s, 3H, major), 3.78 (s, 3H, minor), 3.83 (s, 3H, minor), 3.84 (s, 3H, major), 3.85 (s, 3H, major), 3.87 (s, 3H, major), 3.90 (s, 3H, major), 3.93 (s, 3H, minor), 4.11 (dd, *J* = 11.0, 10.0 Hz, 1H, major), 4.21 (dd, *J* = 9.0, 5.3 Hz, 1H, minor), 4.39 (dd, *J* = 11.0, 1.0 Hz, 1H, major), 5.14 (d, *J* = 10.0 Hz, 1H, major), 5.56 (d, *J* = 9.0 Hz, 1H, minor), 6.50 (s, 1H, major), 6.51

(s, 1H, minor), 6.70-6.79 (m, 3H, major), 6.86 (d, J = 8.4 Hz, 1H, major), 6.87 (d, I = 8.7 Hz, 2H, minor), 7.22-7.31 (m, 3H, major), 7.40 (dd, J = 8.4, 1.8 Hz, 1H, major), 7.48 (dd, J = 8.4, 2.0 Hz, 1H, minor), 7.70 (d, J = 1.0 Hz, 1H, major). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  -0.4 (major), -0.2 (minor), 32.0 (minor), 34.0 (minor), 48.1 (minor). 50.6, 55.1, 55.2 (minor), 55.8, 55.9 (minor), 56.0, 56.1 (minor), 56.2 (minor), 56.3, 76.2 (minor), 80.1, 89.1, 100.7, 100.9 (minor), 102.5 (minor), 102.9, 103.2 (minor), 103.9, 109.7, 109.9 (minor), 110.1, 110.3 (minor), 113.87, 113.93 (minor), 114.3, 122.1 (minor), 123.6, 128.5, 128.8 (minor), 129.6 (minor), 129.7, 131.1, 131.4 (minor), 132.5, 132.8 (minor), 148.7, 149.4 (minor), 153.47, 153.52 (minor), 153.7, 153.78 (minor), 155.80, 156.0 (minor), 159.6 (minor), 159.7, 194.3 (minor), 199.0. IR (UATR):  $\nu_{\rm max}$  2959, 2838, 2172, 1663, 1514, 1248, 1151, 1023, 842 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 610 (18)  $[C_{31}H_{33}^{81}BrO_6Si]^+$ , 608 (1)  $[C_{31}H_{33}^{79}BrO_6Si]^+$ , 298 (30), 165 (100). TOF-HRMS: calcd for  $C_{31}H_{33}^{79}BrNaO_6Si$  (M + Na<sup>+</sup>) 631.1122, found 631.1107; calcd for  $C_{31}H_{33}^{81}BrNaO_6Si$  (M + Na<sup>+</sup>) 633.1107, found 633.1088.

(6-Bromo-2-(3,4-dimethoxyphenyl)-7-methoxy-4-((trimethylsilyl)ethynyl)chroman-3-yl)(3,4-dimethoxyphenyl)methanone (24h). Following the general procedure for the PtCl<sub>4</sub>catalyzed o-QM/[4 + 2] cycloaddition reaction using chalcone 23h, benzyl acetate 15 (0.021 g, 0.050 mmol) furnished chroman 24h as a 9:1 (2,4-cis:2,4-trans) inseparable mixture of diastereomers as a yellow sticky gum (0.023 g, 0.035 mmol, 70%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  -0.06 (s, 9H, major), 0.12 (s, 9H, minor), 3.78 (s, 3H, major), 3.79 (s, 3H, major), 3.85 (s, 6H, major), 3.87 (s, 3H, minor), 3.88 (s, 3H, minor), 3.90 (s, 3H, major), 3.94 (s, 3H, minor), 4.13 (dd, J = 11.0, 10.0 Hz, 1H, major), 4.03 (dd, J = 11.0, 0.9 Hz, 1H, major), 5.12 (d, J = 10.0 Hz, 1H, major), 5.55 (d, I = 9.3 Hz, 1H, minor), 6.52 (s, 1H, major), 6.53 (s, 1H, minor), 6.70 (d, J = 8.1 Hz, 1H, major), 6.75 (d, J = 8.5 Hz, 1H, major), 6.81-6.93 (m, 2H, major), 6.98 (d, J = 1.9 Hz, 1H, minor), 7.04 (dd, *J* = 8.3, 1.9 Hz, 1H, minor), 7.42 (dd, *J* = 8.4, 2.0 Hz, 1H, major), 7.49 (dd, J = 8.5, 1.9 Hz, 1H, minor), 7.71 (d, J = 0.9 Hz, 1H, major). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ -0.4 (major), -0.2 (minor), 32.0 (minor), 33.9 (major), 47.9 (minor), 50.5 (major), 55.8 (major), 55.85 (major), 55.90 (minor), 56.0 (major), 56.1 (minor), 56.2 (minor), 56.3 (major), 80.2 (major), 89.1 (major), 100.7 (major), 101.0 (minor), 102.6 (minor), 103.0 (major), 103.9 (major), 109.7 (major), 109.9 (minor), 110.0 (major), 110.1 (major), 110.3 (minor), 110.8 (minor), 110.9 (major), 111.1 (minor), 114.1 (minor), 114.3 (major), 120.08 (major), 120.14 (minor), 122.1 (minor), 123.6 (major), 129.6 (minor), 130.0 (major), 131.1 (major), 131.7 (minor), 132.6 (minor), 132.9 (major), 148.8 (major), 148.9 (major), 149.2 (major), 153.6 (major), 153.7 (major), 155.8 (major), 194.2 (minor), 198.9 (major). IR (UATR): v<sub>max</sub> 2958, 2838, 2172, 1515, 1262, 1150 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 640 (8)  $[C_{32}H_{35}^{81}BrO_7Si]^+$ , 638 (5)  $[C_{32}H_{35}^{79}BrO_7Si]^+$ , 165 (100). TOF-HRMS: calcd for <sup>79</sup>BrNaO<sub>7</sub>Si (M + Na<sup>+</sup>) 661.1228, found 661.1244; calcd for C32H35  $C_{32}H_{35}^{-81}BrNaO_7Si (M + Na^+) 663.1213$ , found 663.1219.

(6-Bromo-7-methoxy-2-(3,4,5-trimethoxyphenyl)-4-((trimethylsilyl)ethynyl)chroman-3-yl)(3,4-dimethoxyphenyl)methanone (24i). Following the general procedure for the PtCl<sub>4</sub>catalyzed o-QM/[4 + 2] cycloaddition reaction using chalcone 23i, benzyl acetate 15 (0.021 g, 0.050 mmol) furnished chroman 24i as a 5:1 (2,4-cis:2,4-trans) inseparable mixture of diastereomers as a yellow sticky gum (0.013 g, 0.019 mmol, 38%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  -0.05 (s, 9H, major), 0.12 (s, 9H, minor), 3.70 (s, 3H, major), 3.75 (s, 6H, major), 3.81 (s, 3H, minor), 3.84 (s, 6H, minor), 3.85 (s, 3H, major), 3.86 (s, 3H, major), 3.89 (s, 3H, major), 3.95 (s, 3H, minor), 4.12 (dd, J = 11.0, 10.0 Hz, 1H, major), 4.25 (dd, J = 9.1, 5.3 Hz, 1H, minor), 4.43 (dd, J = 11.0, 0.9 Hz, 1H, major), 5.08 (d, J = 10.0 Hz, 1H, major), 5.53 (d, J = 9.1 Hz, 1H, minor), 6.53 (s, 1H, major), 6.54 (s, 1H, minor), 6.56 (s, 2H, major), 6.69 (s, 2H, minor), 6.75 (d, J = 8.5 Hz, 1H, major), 6.87 (d, J = 8.4 Hz, 1H, minor), 7.27 (d, J = 1.9Hz, 1H, major), 7.41 (dd, J = 8.5, 1.9 Hz, 1H, major), 7.51 (dd, J = 8.4, 1.8 Hz, 1H, minor), 7.71 (d, J = 0.9 Hz, 1H, major). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  -0.4 (major), -0.2 (minor), 31.9 (minor), 33.7 (major), 47.8 (major), 50.7 (major), 55.85 (major), 55.92 (minor), 56.05 (major), 56.07 (major), 56.10 (minor), 56.26 (minor), 56.31

(major), 60.66 (major), 60.69 (minor), 76.8 (minor), 80.5 (major), 89.1 (major), 91.4 (minor), 100.7 (major), 100.9 (minor), 102.7 (minor), 103.1 (major), 103.9 (major), 104.4 (major), 104.8 (major), 109.6 (major), 110.0 (minor), 110.1 (major), 110.3 (minor), 114.0 (minor), 114.3 (major), 122.1 (minor), 123.4 (major), 129.6 (minor), 131.2 (major), 132.6 (major), 132.86 (minor), 132.92 (major), 134.6 (minor), 138.2 (minor), 148.8 (major), 153.17 (major), 153.23 (minor), 153.5 (major), 153.6 (major), 155.8 (major), 156.1 (minor), 194.1 (minor), 198.7 (major). IR (UATR):  $\nu_{max}$  2958, 2174, 1664, 1593, 1263, 1126 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 670 (15) [C<sub>33</sub>H<sub>37</sub><sup>81</sup>BrO<sub>8</sub>Si]<sup>+</sup>, 668 (16) [C<sub>33</sub>H<sub>37</sub><sup>79</sup>BrAo<sub>8</sub>Si (M + Na<sup>+</sup>) 691.1333, found 691.1335; calcd for C<sub>33</sub>H<sub>37</sub><sup>81</sup>BrNaO<sub>8</sub>Si (M + Na<sup>+</sup>) 693.1319, found 693.1302.

(6-Bromo-7-methoxy-2-(4-methoxyphenyl)-4-((trimethylsilyl)ethynyl)chroman-3-yl)(3,4,5trimethoxyphenyl)methanone (24j). Following the general procedure for the PtCl<sub>4</sub>-catalyzed o-QM/[4 + 2] cycloaddition reaction using chalcone 23j, benzyl acetate 15 (0.021 g, 0.050 mmol) furnished chroman 24j as a single diastereomer as a pale yellow solid (0.017 g, 0.027 mmol, 53%). Mp (EtOAc/hexanes): 134.6-136.9 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  –0.07 (s, 9H), 3.72 (s, 3H), 3.82 (s, 6H), 3.845 (s, 3H), 3.851 (s, 3H), 4.06 (dd, J = 11.0, 10.0 Hz, 1H), 4.40 (dd, J = 11.0, 0.8 Hz, 1H), 5.14 (d, J = 10.0 Hz, 1H), 6.51 (s, 1H), 6.77 (d, J = 8.3 Hz, 2H), 6.92 (s, 2H), 7.28 (d, J = 8.3 Hz, 2H), 7.69 (d, J = 0.8 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  –0.4, 34.0, 51.4, 55.2, 56.2, 56.3, 60.8, 80.0, 89.3, 100.7, 103.0, 103.7, 105.9, 114.0, 114.1, 128.4, 129.8, 132.5, 133.2, 142.7, 152.7, 153.7, 155.9, 159.9, 199.7. IR (UATR):  $\nu_{\text{max}}$  2958, 2172, 1668, 1249, 1150 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 640 (9)  $[C_{32}H_{35}^{81}BrO_7Si]^+$ , 638 (9)  $[C_{32}H_{35}^{79}BrO_7Si]^+$ , 195 (100), 178 (49). TOF-HRMS: calcd for  $C_{32}H_{35}^{79}BrNaO_7Si$  (M + Na<sup>+</sup>) 661.1228, found 661.1210; calcd for  $C_{32}H_{35}^{81}BrNaO_7Si (M + Na^+) 663.1213, found 663.1198.$ 

(6-Bromo-2-(3,4-dimethoxyphenyl)-7-methoxy-4-((trimethylsilyl)ethynyl)chroman-3-yl)(3,4,5trimethoxyphenyl)methanone (24k). Following the general procedure for the  $PtCl_4$ -catalyzed o-QM/[4 + 2] cycloaddition reaction using chalcone 23k, benzyl acetate 15 (0.021 g, 0.050 mmol) furnished chroman 24k as a single diastereomer as a yellow sticky gum (0.014 g, 0.021 mmol, 42%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 0.06$  (s, 9H), 3.78 (s, 3H), 3.79 (s, 3H), 3.82 (s, 6H), 3.86 (s, 3H), 4.09 (dd, J = 11.0, 10.0 Hz, 1H), 4.41 (dd, J = 11.0, 1.0 Hz, 1H), 5.12 (d, J = 10.0 Hz, 1H), 6.53 (s, 1H), 6.73 (d, J = 8.2 Hz, 1H), 6.86 (d, J = 1.8 Hz, 1H), 6.91 (dd, J = 8.2, 1.8 Hz, 1H), 6.94 (s, 1H), 7.70 (d, J = 1.0 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  –0.4, 34.0, 51.3, 55.8, 55.9, 56.2, 56.4, 60.9, 80.2, 89.3, 100.8, 103.1, 103.8, 106.0, 110.0, 111.1, 114.2, 120.0, 130.1, 132.6, 133.2, 142.9, 149.0, 152.8, 153.6, 155.9, 199.6. IR (UATR):  $\nu_{\rm max}$  2957, 2837, 2173, 1668, 1580, 1126 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 670 (11)  $[C_{33}H_{37}^{81}BrO_8Si]^+$ , 668 (10) [C<sub>33</sub>H<sub>37</sub><sup>79</sup>BrO<sub>8</sub>Si]<sup>+</sup>, 195 (100). TOF-HRMS: calcd for  $C_{33}H_{37}^{79}BrNaO_8Si (M + Na^+) 691.1333$ , found 691.1345; calcd for  $C_{33}H_{37}^{81}BrNaO_8Si (M + Na^+) 693.1319$ , found 693.1318.

(6-Bromo-7-methoxy-2-(3,4,5-trimethoxyphenyl)-4-((trimethylsilyl)ethynyl)chroman-3-yl)(3,4,5trimethoxyphenyl)methanone (24l). Following the general procedure for the PtCl<sub>4</sub>-catalyzed o-QM/[4 + 2] cycloaddition reaction using chalcone 23l, benzyl acetate 15 (0.021 g, 0.050 mmol) furnished chroman 24l as a 5:1 (2,4-cis:2,4-trans) inseparable mixture of diastereomers as a yellow sticky gum (0.015 g, 0.021 mmol, 41%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>2</sub>):  $\delta$  –0.44 (s, 9H, major), 0.13 (s, 9H, minor), 3.72 (s, 3H, major), 3.75 (s, 6H, major), 3.82 (s, 6H, major), 3.85 (s, 6H, minor), 3.856 (s, 3H, major), 3.861 (s, 3H, major), 3.88 (s, 6H, minor), 3.92 (s, 3H, minor), 4.08 (dd, J = 11.0, 10.0 Hz, 1H, major), 4.43 (dd, J = 11.0, 1.0 Hz, 1H, major), 5.08 (d, J = 10.0 Hz, 1H, major), 5.51 (d, J = 8.6 Hz, 1H, minor), 6.54 (s, 1H, major), 6.56 (s, 2H, major), 6.69 (s, 2H, minor), 6.94 (s, 2H, major), 7.10 (s, 2H, minor), 7.44 (s, 1H, minor), 7.71 (d, J = 1.0 Hz, 1H, major). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  –0.4 (major), –0.2 (minor), 31.7 (minor), 33.7 (major), 48.2 (minor), 51.4 (major), 56.1 (major), 56.2 (major), 56.29 (minor), 56.34 (major), 56.4 (minor), 60.7

(major), 60.85 (major), 60.92 (minor), 80.4 (major), 89.2 (major), 100.7 (major), 100.9 (minor), 103.2 (major), 103.8 (major), 104.4 (major), 104.9 (minor), 105.7 (minor), 105.9 (major), 113.9 (minor), 114.1 (major), 131.7 (minor), 132.6 (major), 132.9 (minor), 133.0 (major), 133.3 (major), 134.5 (minor), 138.3 (minor), 142.9 (minor), 152.8 (major), 153.28 (major), 153.31 (major), 153.4 (major), 153.5 (minor), 155.9 (major), 156.1 (minor), 194.5, (minor), 199.4 (major). IR (UATR):  $\nu_{max}$  2941, 28.8, 2176, 1668, 1582, 1124, 842 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 700 (17) [ $C_{34}H_{39}^{81}BrO_9Si$ ]<sup>+</sup>, 698 (13) [ $C_{34}H_{39}^{79}BrO_9Si$ ]<sup>+</sup>, 388 (22), 195 (100). TOF-HRMS: calcd for  $C_{34}H_{43}^{81}BrNO_9Si$  (M + NH<sub>4</sub><sup>+</sup>) 716.1885, found 716.1873; calcd for  $C_{34}H_{43}^{81}BrNO_9Si$  (M + NH<sub>4</sub><sup>+</sup>) 718.1872, found 718.1867.

(6-Bromo-7-methoxy-2-(4-methoxyphenyl)-4-((trimethylsilyl)ethynyl)chroman-3-yl)(4-methoxyphenyl)methyl Acetate (25). Diisobutylaluminum hydride (DIBAL-H; 1.0 M in toluene, 0.17 mL, 0.17 mmol) was added to a solution of chroman 24a (0.076 g, 0.13 mmol) in toluene (2 mL) at 0 °C. The reaction mixture was stirred at that temperature for 1 h. The mixture was then quenched with water (0.1 mL) and 15% NaOH (0.1 mL) sequentially at -78 °C. The reaction mixture was warmed to room temperature, and water (0.3 mL) was added. Na<sub>2</sub>SO<sub>4</sub> was then added, and the mixture was filtered through Celite. The filtrate was evaporated (aspirator then vacuum) to give a crude product, which was used in the next step without further purification.

A solution of the benzyl alcohol and DMAP (0.024 g, 0.20 mmol) in DCM (1.5 mL) was cooled in an ice bath for 10 min before Et<sub>3</sub>N (28  $\mu$ L, 0.20 mmol) and Ac<sub>2</sub>O (19  $\mu$ L, 0.20 mmol) were added successively. The mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with water (2 mL), and the resulting mixture was extracted with DCM ( $3 \times 2$  mL). The combined organic phases were washed with water  $(3 \times 2 \text{ mL})$  and brine (2 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a crude product which was purified by column chromatography on silica (15-30% EtOAc/hexanes) to give the desired product 25 as a white solid (0.075 g, 0.12 mmol, 93%).  $^1\mathrm{H}$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  0.14 (s, 9H), 2.92 (td, J = 8.1, 4.4 Hz, 1H), 3.73–3.78 (m, 1H), 3.77 (s, 3H), 3.79 (s, 3H), 3.80 (s, 3H), 4.90 (d, J = 8.1 Hz, 1H), 5.97 (d, J = 4.4 Hz, 1H), 6.41 (s, 1H), 6.73 (d, J = 8.7 Hz, 2H), 6.80 (d, J = 8.7 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 7.20 (d, J = 8.7 Hz, 2H),7.55 (d, J = 0.7 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  -0.0, 21.1, 30.3, 47.4, 55.2, 55.4, 56.2, 74.6, 78.1, 87.8, 100.7, 102.9, 106.4, 113.6, 113.8, 114.4, 127.5, 129.0, 129.8, 130.2, 133.4, 153.5, 155.7, 156.0, 159.7, 167.7. TOF-HRMS: calcd for  $C_{32}H_{35}^{-79}BrNaO_6Si$  (M + Na<sup>+</sup>) 645.1278, found 645.1285; calcd for  $C_{32}H_{35}^{-81}BrNaO_6Si$  (M + Na<sup>+</sup>) 647.1264, found 647.1250.

(6-Bromo-7-methoxy-2-(4-methoxyphenyl)-4-vinylchroman-3-yl)(4-methoxyphenyl)methyl Acetate (26). To a solution of chroman TMS acetylide 25 (0.075 g, 0.12 mmol) in THF (2 mL) was added tetrabutylammonium fluoride (TBAF; 0.059 g, 0.18 mmol) at 0 °C, and the reaction mixture was kept at this temperature for 3 h. The reaction mixture was quenched with water (2 mL), and the resulting mixture was extracted with EtOAc (3 × 2 mL). The combined organic phases were washed with water (3 × 2 mL) and brine (2 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a crude product, which was used in the next step without further purification.

A suspension of the chroman alkyne and Pd on CaCO<sub>3</sub> (0.051 g, 0.024 mmol) in DCM (7 mL) was stirred at room temperature under an H<sub>2</sub> atmosphere. After the mixture was stirred for 24 h, the palladium catalyst was removed by filtration through Celite and the filtrate was concentrated under reduced pressure to give the crude product, which was further purified by column chromatography on silica (15–30% EtOAc/hexanes) to give the desired product **26** as a white sticky gum (0.059 g, 0.11 mmol, 89%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  2.09 (s, 3H), 2.66–2.75 (m, 1H), 3.27 (t, *J* = 8.3 Hz, 1H), 3.75 (s, 3H), 3.77 (s, 3H), 3.82 (s, 3H), 4.97 (dd, *J* = 16.9, 1.3 Hz, 1H), 5.03 (dd, *J* = 9.9, 1.3 Hz, 1H), 5.12 (d, *J* = 6.8 Hz, 1H), 5.41 (ddd, *J* = 16.9, 9.9, 8.3 Hz, 1H), 5.92 (d, *J* = 5.4 Hz, 1H), 6.69 (d, *J* = 8.7 Hz, 2H), 6.75 (d, *J* = 8.7 Hz, 2H), 6.88 (d, *J* = 8.7 Hz, 2H), 7.12 (d, *J* = 8.7 Hz, 2H), 7.18 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  21.0,

41.7, 48.0, 55.2, 55.3, 56.2, 74.5, 77.3, 100.9, 102.7, 113.5, 113.7, 116.3, 117.1, 127.3, 128.4, 130.7, 131.0, 133.9, 140.0, 154.1, 155.3, 158.8, 159.3, 169.7. TOF-HRMS: calcd for  $C_{29}H_{29}^{-79}BrNaO_6$  (M + Na<sup>+</sup>) 575.1040, found 575.1038; calcd for  $C_{29}H_{29}^{-81}BrNaO_6$  (M + Na<sup>+</sup>) 577.1024, found 577.1037.

General Procedure for the Desilylation Using  $Cs_2CO_3$  in Methanol. To a solution of ketone chroman TMS acetylide 24 (1.0 equiv) in 1/1 THF/MeOH (20 mL mmol<sup>-1</sup>) was added  $Cs_2CO_3$  (2.0 equiv) at 0 °C, and the reaction mixture was stirred at a temperature between 5 and 9 °C until the starting material was consumed, as indicated by TLC (typically 3–4 h). Water and EtOAc were added, and the mixture was concentrated under reduced pressure. The residue was extracted with EtOAc, and the combined organic phases were washed with water and brine, dried over NaSO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a crude product, which was further purified by column chromatography on silica to give the desilylated product.

(6-Bromo-4-ethynyl-7-methoxy-2-(4-methoxyphenyl)chroman-3-yl)(4-methoxyphenyl)methanone (28). Following the general procedure for the desilylation using Cs2CO3, ketone chroman TMS acetylide 24a (0.075 g, 0.13 mmol) was converted to the corresponding ketone chroman alkyne 28, which was obtained as a pale yellow solid (0.060 g, 0.12 mmol, 91%). Mp (EtOAc/hexanes): 167.6–168.8 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  2.11 (d, J = 2.4 Hz, 1H), 3.70 (s, 3H), 3.81 (s, 3H), 3.85 (s, 3H), 4.11 (dd, J = 11.0, 10.0 Hz, 1H), 4.45 (ddd, J = 11.0, 2.4, 1.0 Hz, 1H), 5.07 (d, J = 10.0 Hz, 1H), 6.51 (s, 1H), 6.72 (d, J = 8.7 Hz, 2H), 6.78 (d, J = 8.9 Hz, 2H), 7.24 (d, J = 8.7 Hz, 2H), 7.70 (d, J = 8.9 Hz, 2H), 7.72 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 32.4, 50.5, 55.1, 55.3, 56.2, 72.1, 80.2, 82.2, 100.7, 102.9, 113.5, 113.8, 114.0, 128.4, 129.4, 130.6, 130.7, 132.4, 153.8, 155.8, 159.7, 163.6, 198.5. IR (UATR): ν<sub>max</sub> 3292, 2937, 2170, 1664, 1599, 1260, 1154, 1030 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 508 (9)  $[C_{27}H_{24}^{81}BrO_5]^+$ , 506 (14)  $[C_{27}H_{24}^{79}BrO_5]^+$ , 135 (100). TOF-HRMS: calcd for  $C_{27}H_{24}^{79}BrO_5$  (M + H<sup>+</sup>) 507.0802, found 507.0784; calcd for  $C_{27}H_{24}^{81}BrO_5$  (M + H<sup>+</sup>) 509.0785, found 509.0791

(6-Bromo-2-(3,4-dimethoxyphenyl)-4-ethynyl-7-methoxychroman-3-yl)(3-methoxyphenyl)methanone (35a). Following the general procedure for the desilylation using Cs<sub>2</sub>CO<sub>3</sub>, ketone chroman TMS acetylide 24e (0.188 g, 0.309 mmol) was converted to the corresponding ketone chroman alkyne 35a, which was obtained as a yellow sticky gum (0.143 g, 0.266 mmol, 86%). <sup>1</sup>H NMR (300 MHz,  $CDCl_3$ :  $\delta 2.16$  (d, J = 2.4 Hz, 1H), 3.75 (s, 6H), 3.76 (s, 3H), 3.84 (s, 3H), 4.17 (dd, J = 10.6, 9.9 Hz, 1H), 4.47 (ddd, J = 10.6, 2.4, 0.7 Hz, 1H), 5.02 (d, J = 9.9 Hz, 1H), 6.52 (s, 1H), 6.68 (d, J = 8.2 Hz, 1H), 6.81 (d, J = 1.8 Hz, 1H), 6.86 (dd, J = 8.2, 1.8 Hz, 1H), 6.99 (dd, J = 8.2, 1.8 Hz, 1H), 7.17 (d, J = 1.8 Hz, 1H), 7.20 (dd, J = 8.2, 7.8 Hz, 1H), 7.29 (br d, J = 7.8 Hz, 1H), 7.73 (d, J = 0.7 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 32.4, 51.4, 55.3, 55.79, 55.81, 56.3, 72.2, 80.4, 82.1, 100.8, 103.2, 110.0, 110.9, 112.4, 113.8, 119.7, 120.2, 120.9, 129.2, 129.4, 132.5, 139.1, 148.9, 149.3, 153.7, 155.9, 159.4, 200.3. IR (UATR):  $\nu_{\text{max}}$  3288, 2937, 2836, 1672, 1595, 1262, 1152, 1026 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 538 (18)  $[C_{28}H_{25}^{-81}BrO_6]^+$ , 536 (19)  $[C_{28}H_{25}{}^{79}BrO_6]^+,\ 403\ (35),\ 401\ (37).$  TOF-HRMS: calcd for  $C_{28}H_{26}{}^{79}BrO_6\ (M\ +\ H^+)\ 537.0907,\ found\ 537.0912;\ calcd\ for$  $\begin{array}{l} C_{28} {H_{26}}^{79} BrO_6 \ \left(M \ + \ H^+\right) \ 537.0907, \ found \ 537.0907, \\ C_{28} {H_{26}}^{81} BrO_6 \ \left(M \ + \ H^+\right) \ 539.0888, \ found \ 539.0878. \end{array}$ 

(6-Bromo-4-ethynyl-7-methoxy-2-(4-methoxyphenyl)chroman-3-yl)(3,4-dimethoxyphenyl)methanone (35b). Following the general procedure for the desilylation using Cs<sub>2</sub>CO<sub>3</sub>, ketone chroman TMS acetylide 24g (0.103 g, 0.170 mmol) was converted to the corresponding ketone chroman alkyne 35b, which was obtained as a yellow sticky gum (0.089 g, 0.165 mmol, 97%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.13 (d, J = 2.4 Hz, 1H), 3.70 (s, 3H), 3.84 (s, 6H), 3.89 (s, 3H), 4.11 (dd, J = 11.0, 10.1 Hz, 1H), 4.46 (ddd, J = 11.0, 2.4, 1.0 Hz, 1H), 5.08 (d, J = 10.1 Hz, 1H), 6.51 (s, 1H), 6.73 (d, J = 8.9 Hz, 2H), 6.74 (d, J = 8.5 Hz, 1H), 7.248 (d, J = 8.9 Hz, 2H), 7.249 (d, J = 2.0Hz, 1H), 7.36 (dd, J = 8.5, 2.0 Hz, 1H), 7.72 (d, J = 1.0, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 32.5, 50.5, 55.1, 55.8, 55.9, 56.2, 72.2, 80.1, 82.2, 100.7, 102.9, 109.7, 110.1, 113.8, 113.9, 123.5, 128.4, 129.4, 130.8, 132.4, 148.6, 153.4, 153.7, 155.8, 159.7, 198.5. IR (UATR):  $ν_{max}$  3290, 2922, 2852, 1661, 1514, 1262 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 554 (13)  $[C_{29}H_{29}^{81}BrO_6]^+$ , 552 (14)  $[C_{29}H_{29}^{79}BrO_6]^+$ , 374 (16), 372, (20), 165 (100). TOF-HRMS: calcd for  $C_{29}H_{29}^{79}BrNaO_6$  (M + Na<sup>+</sup>) 575.1040, found 575.1036; calcd for  $C_{29}H_{29}^{81}BrNaO_6$  (M + Na<sup>+</sup>) 577.1021, found 577.1025.

(6-Bromo-2-(3,4-dimethoxyphenyl)-4-ethynyl-7-methoxychroman-3-yl)(3,4-dimethoxyphenyl)methanone (35c). Following the general procedure for the desilvlation using Cs<sub>2</sub>CO<sub>3</sub>, ketone chroman TMS acetylide 24h (0.321 g, 0.502 mmol) was converted to the corresponding ketone chroman alkyne 35c, which was obtained as a yellow sticky gum (0.252 g, 0.442 mmol, 88%). <sup>1</sup>H NMR (300 MHz,  $CDCl_3$ ):  $\delta 2.14$  (d, J = 2.4 Hz, 1H), 3.77 (s, 3H), 3.78 (s, 3H), 3.84 (s, 6H), 3.89 (s, 3H), 4.13 (t, J = 10.5 Hz, 1H), 4.46 (br d, J = 10.5 Hz, 1H), 5.07 (d, J = 10.5 Hz, 1H), 6.52 (s, 1H), 6.68 (d, J = 8.1 Hz, 1H), 6.73 (d, J = 8.5 Hz, 1H), 6.88–6.91 (m, 2H), 7.26 (d, J = 1.2 Hz, 1H), 7.38 (dd, J = 8.5 Hz, 1H), 7.73 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  50.5, 55.76, 55.81, 55.9, 56.3, 72.2, 80.3, 82.2, 100.7, 103.1, 109.7, 110.0, 110.1, 110.9, 113.9, 119.9, 123.4, 129.7, 130.8, 132.5, 148.7, 148.9, 149.2, 153.60, 153.65, 155.8, 198.5. IR (UATR):  $\nu_{\rm max}$  2936, 1661, 1593, 1515, 1260, 1148, 1021 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 568 (17)  $[C_{29}H_{27}^{81}BrO_7]^+$ , 566 (17)  $[C_{29}H_{27}^{79}BrO_7]^+$ , 165 (100). TOF-HRMS: calcd for  $C_{29}H_{27}^{79}BrNaO_7$  (M + Na<sup>+</sup>) 589.0832, found 589.0821; calcd for  $C_{29}H_{27}^{81}BrNaO_7$  (M + Na<sup>+</sup>) 591.0817, found 591.0805.

General Procedure for the Lindlar Hydrogenation and Allyl Grignard Addition. A suspension of ketone chroman alkyne (1 equiv) and Pd on CaCO<sub>3</sub> (30 mol %) in DCM (30 mL mmol<sup>-1</sup>) was stirred at room temperature under an H<sub>2</sub> atmosphere (300 psi). After the mixture was stirred for 5 h, the palladium catalyst was removed by filtration through Celite and the filtrate was concentrated under reduced pressure to give the crude corresponding ketone chroman alkene product, which was used in the next step without further purification.

To a solution of the ketone chroman alkene in 1/2 THF/Et<sub>2</sub>O (20 mL mmol<sup>-1</sup>) was added allylmagnesium bromide (1.0 M in Et<sub>2</sub>O, 2.5 equiv) at 0 °C. The mixture was stirred and slowly warmed to 10 °C, at which it was stirred for an additional 18 h. The reaction mixture was quenched with saturated NH<sub>4</sub>Cl. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a crude product, which was further purified by column chromatography on silica (0–30% EtOAc/hexanes) to give the desired diene alcohol product.

1-(6-Bromo-7-methoxy-2-(4-methoxyphenyl)-4-vinylchroman-3-yl)-1-(4-methoxyphenyl)but-3-en-1-ol (29). Following the general procedure for the Lindlar hydrogenation and allyl Grignard addition, ketone chroman alkyne 28 (0.070 g, 0.14 mmol) was converted to the corresponding diene alcohol 29, which was obtained as a 2:1 inseparable mixture of diastereomers as a white sticky gum (0.063 g, 0.11 mmol, 82%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.32 (s, 1H, minor), 2.40 (s, 1H, major), 2.40-2.49 (m, 1H, minor), 2.58-2.66 (m, 1H, major), 2.78 (d, J = 7.1 Hz, 1H, major), 3.02 (dd, J = 13.7, 5.5 Hz, 1H, minor), 3.51-3.60 (m, 1H, major), 3.74 (s, 3H, major), 3.81 (s, 3H, major), 3.88 (s, 3H, major), 4.53-4.71 (m, 2H, major), 4.96–5.20 (m, 3H, major), 5.46–5.64 (m, 2H, major), 6.53 (s, 1H, minor), 6.56, (s, 1H, major), 6.73 (d, J = 8.8 Hz, 2H, major), 6.74 (d, J = 8.9 Hz, 2H, minor), 6.88 (d, J = 9.0 Hz, 2H, minor), 6.89 (d, J = 8.7 Hz, 2H, major), 6.96 (d, J = 9.0 Hz, 2H, minor), 6.99 (d, J = 8.7 Hz, 2H, major), 7.11 (s, 1H, minor), 7.14 (s, 1H, major), 7.39 (d, J = 8.8 Hz, 2H, major), 7.42 (d, J = 8.9 Hz, 2H, minor). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 37.4, 37.8 (minor), 42.2, (minor), 42.4 (major), 54.0 (major), 55.1 (major), 55.2 (major), 56.1 (major), 74.4 (minor), 74.5 (major), 78.0 (minor), 78.3 (major), 100.7 (minor), 100.8 (major), 102.6 (major), 102.7 (minor), 113.4 (minor), 113.45 (major), 113.51 (minor), 113.6 (major), 113.68 (minor), 113.70 (major), 117.5 (major), 118.0 (minor), 120.0 (major), 120.2 (minor), 126.7 (major), 126.8 (minor), 127.2 (major), 127.5 (minor), 133.1 (major), 133.2 (minor), 133.4 (minor), 133.6 (major), 133.69 (minor), 133.71 (major), 136.4 (minor), 136.7 (major), 141.8, (minor), 142.0 (major), 153.1 (major), 153.3 (minor), 155.17 (minor), 155.22 (major), 158.3

(major), 158.4 (minor), 158.48 (major), 158.53 (minor). IR (UATR):  $\nu_{\rm max}$  3547, 2935, 1610, 1510 1247, 1153 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 552 (1)  $[C_{30}H_{31}^{81}BrO_5]^+$ , 550 (1)  $[C_{30}H_{31}^{79}BrO_5]^+$ , 376 (16), 374 (17), 135 (100), 121 (30). TOF-HRMS: calcd for  $C_{30}H_{31}^{79}BrNaO_5$  (M + Na<sup>+</sup>) 573.1247, found 573.1262; calcd for  $C_{30}H_{31}^{81}BrNaO_5$  (M + Na<sup>+</sup>) 575.1232, found 575.1203.

1-(6-Bromo-2-(3,4-dimethoxyphenyl)-7-methoxy-4-vinylchroman-3-yl)-1-(3-methoxyphenyl)but-3-en-1-ol (36a). Following the general procedure for the Lindlar hydrogenation and allyl Grignard addition, ketone alkyne 35a (0.106 g, 0.198 mmol) was converted to the corresponding diene alcohol 36a, which was obtained as a 3:1 inseparable mixture of diastereomers as a yellow sticky gum (0.113 g, 0.194 mmol, 98%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.39 (s, 1H, minor), 2.44 (s, 1H, major), 2.65-2.71 (m, 1H), 2.74-2.83 (m, 1H), 3.01 (dd, J = 13.9, 5.6 Hz, 1H, minor), 3.57 (d, J = 8.3 Hz, 1H, minor), 3.64 (d, J = 8.3 Hz, 1H, major), 3.72 (s, 3H), 3.80 (s, 3H), 3.81 (s, 3H), 3.86 (s, 3H), 4.62-4.78 (m, 2H), 5.03-5.26 (m, 3H), 5.39-5.63 (m, 2H), 6.55 (s, 1H, minor), 6.57 (s, 2H, major), 6.60-6.74 (m, 2H), 6.75-6.84 (m, 1H), 6.97-7.10 (m, 2H), 7.12 (s, 1H, minor), 7.18 (s, 1H, major), 7.22-7.32 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>2</sub>):  $\delta$  37.7 (major), 37.9 (minor), 42.4 (minor), 43.1 (major), 53.8 (major), 53.9 (minor), 55.1 (major), 55.2 (major), 55.70 (major), 55.73 (minor), 55.8 (major), 56.2 (major), 74.6 (minor), 75.1 (major), 78.3 (minor), 78.7 (major), 100.7 (minor), 100.8 (major), 102.8 (major), 109.3 (major), 109.4 (minor), 110.7 (major), 110.8 (minor), 111.8 (major), 112.2 (minor), 112.6 (major), 112.7 (minor), 113.7 (minor), 113.9 (major), 117.8 (major), 118.0 (major), 118.1 (minor), 118.3 (major), 118.7 (minor), 120.1 (major), 120.4 (minor), 129.1 (minor), 129.3 (major), 132.9 (major), 133.1 (minor), 133.7 (major), 133.9 (minor), 134.1 (major), 141.9 (minor), 142.1 (major), 146.2 (major), 146.6 (major), 147.8 (major), 148.6 (major), 153.3 (major), 153.4 (minor), 155.3 (major), 159.7 (minor), 159.8 (major). IR (UATR):  $\nu_{\rm max}$  3546, 2937, 1607, 1515, 1257, 1144, 1027 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 582 (1)  $[C_{31}H_{33}^{81}BrO_6]^+$ , 580 (1)  $[C_{31}H_{33}^{79}BrO_6]^+$ , 178 (84), 135 (100). TOF-HRMS: calcd for  $C_{31}H_{33}^{79}BrNaO_6$  (M + Na<sup>+</sup>) 603.1353, found 603.1348; calcd for  $C_{31}H_{33}^{79}BrNaO_6$  (M + Na ) 005.1505, come  $C_{31}H_{33}^{81}BrNaO_6$  (M + Na<sup>+</sup>) 605.1338, found 605.1340.

1-(6-Bromo-7-methoxy-2-(4-methoxyphenyl)-4-vinylchroman-3-yl)-1-(3,4-dimethoxyphenyl)but-3-en-1-ol (36b). Following the general procedure for the Lindlar hydrogenation and allyl Grignard addition, ketone alkyne 35b (0.089 g, 0.166 mmol) was converted to the corresponding diene alcohol 36b, which was obtained as a 2:1 inseparable mixture of diastereomers as a yellow sticky gum (0.086 g, 0.149 mmol, 90%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.35-2.50 (m, 1H), 2.59-2.67 (m, 1H), 2.75-2.83 (m, 1H), 2.97-3.07 (m, 1H, minor), 3.55-3.64 (m, 1H), 3.74 (s, 3H), 3.88 (s, 6H), 3.89 (s, 3H), 4.57-4.74 (m, 2H), 4.96-5.25 (m, 3H), 5.35-5.67 (m, 2H), 6.53 (s, 1H, minor), 6.56 (s, 1H, major), 6.65-6.79 (m, 2H), 6.79-6.90 (m, 1 Hz), 6.90-7.06 (m, 4H), 7.06-7.10 (m, 1H, minor), 7.11 (s, 1H, minor), 7.15 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  37.6 (major), 37.9 (minor), 42.2 (minor), 42.8 (major), 53.87 (major), 53.92 (minor), 55.1 (major), 55.78 (minor), 55.81 (major), 56.0 (major), 56.1 (major), 74.3 (minor), 74.8 (major), 78.1 (minor), 78.5 (major), 100.7 (minor), 100.9 (major), 102.6 (major), 109.6 (major), 109.9 (minor), 110.4 (minor), 110.7 (major), 113.5 (major), 113.6 (minor), 113.7 (minor), 113.8 (major), 117.6 (major), 117.8 (minor), 118.3 (major), 118.7 (minor), 120.1 (major), 120.3 (minor), 126.7 (major), 129.1 (minor), 133.06 (major), 133.14 (minor), 133.4 (minor), 133.57 (major), 133.63 (major), 133.7 (minor), 136.9 (minor), 137.3 (major), 141.8 (minor), 142.0 (major), 147.9 (major), 148.0 (minor), 148.8 (minor), 148.9 (major), 153.2 (major), 153.3 (major), 155.2 (major), 158.3 (major), 158.4 (minor). IR (UATR):  $\nu_{\rm max}$  3546, 2935, 2835, 1610, 1512, 1252, 1151, 1028 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 582 (0.3)  $[C_{31}H_{33}^{-81}BrO_6]^+$ , 580 (1)  $[C_{31}H_{33}^{-79}BrO_6]^+$ , 165 (100). TOF-HRMS: calcd for  $C_{31}H_{33}^{-79}BrNaO_6$  $(M + Na^{+})$  603.1353, found 603.1338; calcd for  $C_{31}H_{33}^{81}BrNaO_{6}$  (M + Na<sup>+</sup>) 605.1338, found 605.1347.

1-(6-Bromo-2-(3,4-dimethoxyphenyl)-7-methoxy-4-vinylchroman-3-yl)-1-(3,4-dimethoxyphenyl)but-3-en-1-ol (36c). Following the general procedure for the Lindlar hydrogenation and allyl Grignard addition, ketone alkyne 35c (0.375 g, 0.661 mmol) was converted to the corresponding diene alcohol 36c, which was obtained as a 4:1 inseparable mixture of diastereomers as a yellow sticky gum (0.376 g, 0.614 mmol, 93%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.38-2.51 (m, 1H), 2.66 (s, 1H, major), 2.80 (d, I = 7.3 Hz, 1H), 3.05 (dd, I= 13.9, 5.6 Hz, 1H, minor), 3.57–3.66 (m, 1H), 3.73 (s, 3H, minor), 3.74 (s, 3H, major), 3.82 (s, 3H, major), 3.88 (s, 3H, major), 3.885 (s, 3H), 3.889 (s, 3H), 3.394 (s, 3H, minor), 4.61-4.78 (m, 2H), 5.04-5.27 (m, 3H), 5.45-5.69 (m, 2H), 6.54, (s, 1H, minor), 6.57 (s, 1H, major), 6.58–6.68 (m, 2H), 6.71 (d, J = 8.4 Hz, 1H, major), 6.72 (d, J = 8.4 Hz, 1H, minor), 6.837 (d, I = 8.5 Hz, 1H, minor), 6.844 (d, I =8.3 Hz, 1H, major), 6.96 (dd, J = 8.4, 2.1 Hz, 1H, major), 6.99-7.04 (m, 1H, major), 7.10 (d, J = 2.0 Hz, 1H, minor), 7.13 (s, 1H, minor), 7.18 (s, 1H, major), 7.28 (s, 1H, minor).<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 37.7 (major), 37.9 (minor), 42.1 (minor), 42.9 (major), 54.0, (minor), 54.1 (major), 55.7 (major), 55.80 (major), 55.83 (minor), 55.9 (major), 56.0 (major), 56.2 (major), 74.4 (minor), 75.1 (major), 78.1 (major), 78.4 (major), 100.6 (minor), 100.9 (major), 102.8 (major), 109.3 (minor), 109.4 (major), 109.7 (major), 109.9 (minor), 110.5 (minor), 110.7 (major), 110.8 (major), 113.8 (minor), 113.9 (major), 117.8 (major), 117.9 (major), 118.0 (major), 118.1 (major), 118.4 (major), 118.8 (minor), 120.2 (major), 120.4 (minor), 133.1 (major), 133.2 (minor), 133.6 (major), 133.7 (minor), 133.9 (minor), 134.2 (major), 136.9 (major), 137.2 (major), 141.9 (minor), 142.1 (major), 147.8 (major), 147.9 (minor), 148.0 (major), 148.1 (minor), 148.6 (major), 148.7 (minor), 148.8 (minor), 148.9 (major), 153.3 (major), 153.4 (minor), 155.3 (major). IR (UATR):  $\nu_{\rm max}$  3534, 2935, 1608, 1514, 1256, 1144, 1025 cm<sup>-1</sup>. TOF-HRMS: calcd for  $C_{32}H_{35}^{-79}BrNaO_7$  (M + Na<sup>+</sup>) 633.1458, found 633.1445; calcd for  $C_{32}H_{35}^{81}BrNaO_7 (M + Na^+) 635.1444$ , found 635.1437.

**General Procedure for the BF<sub>3</sub>·Et<sub>2</sub>O-Mediated Et<sub>3</sub>SiH Reduction.** A solution of alcohol (1.0 equiv) in DCM (10 mL mmol<sup>-1</sup>) was cooled in an ice bath for 5 min. At this time, Et<sub>3</sub>SiH (10 equiv) and BF<sub>3</sub>·Et<sub>2</sub>O (1.5 equiv) were added to the reaction mixture successively. The stirring was continued (for the time and temperature indicated for each substrate). When the reaction was complete, water was added to quench the reaction. The aqueous layer was extracted with DCM, and the combined organic phases were washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to give a crude product, which was further purified by PTLC to give the desired product.

6-Bromo-7-methoxy-2-(4-methoxyphenyl)-3-(1-(4methoxyphenyl)but-3-en-1-yl)-4-vinylchroman (27). Following the general procedure for the BF<sub>3</sub>·Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction at 0 °C for 2 h, diene alcohol 29 (0.016 g, 0.029 mmol) furnished the diene 27 as a yellow sticky gum (0.013 g, 0.025 mmol, 86%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.82-1.93 (m, 1H), 1.95-2.07 (m, 1H), 2.20 (dt, J = 6.8, 1.7 Hz, 1H), 2.70 (ddd, J = 10.1, 6.8, 5.6 Hz, 1H), 3.11-3.16 (m, 1H), 3.73 (s, 3H), 3.85 (s, 3H), 3.86 (s, 3H), 4.62 (dd, J = 17.0, 2.1 Hz, 1H), 4.68 (dd, J = 10.2, 2.1 Hz, 1H), 4.78 (dt, J = 17.0, 1.5 Hz, 1H), 5.17 (dt, J = 10.1, 1.3 Hz, 1H), 5.17–5.30 (m, 2H), 5.98 (ddd, J = 17.0, 10.2, 5.5 Hz, 1H), 6.42 (s, 1H), 6.62 (d, J = 8.7 Hz, 1H)2H), 6.75 (d, J = 8.7 Hz, 2H), 6.83 (s, 1H), 6.98 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.6 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  39.6, 41.8, 42.1, 46.3, 55.2, 55.3, 56.2, 74.6, 100.6, 102.1, 113.0, 113.8, 115.3, 115.6, 117.2, 126.4, 129.6, 132.4, 134.4, 137.1, 142.9, 154.9, 155.2, 157.9, 158.8. IR (UATR): ν<sub>max</sub> 2932, 2836, 1610, 1511, 1246, 1156 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 536 (7)  $[C_{30}H_{31}^{81}BrO_4]^+$ , 543 (5)  $[C_{30}H_{31}^{-79}BrO_4]^+$ , 253 (100), 161 (95). TOF-HRMS: calcd for C30H35 <sup>9</sup>BrNO<sub>4</sub> (M + NH<sub>4</sub><sup>+</sup>) 552.1744, found 552.1742; calcd for  $C_{30}H_{31}^{81}BrNO_4$  (M + NH<sub>4</sub><sup>+</sup>) 554.1729, found 554.1729.

**6-Bromo-3-(1-(3,4-dimethoxyphenyl)but-3-en-1-yl)-7-me-thoxy-2-(4-methoxyphenyl)-4-vinylchroman (37b).** Following the general procedure for the BF<sub>3</sub>·Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction at 0 °C for 1 h, diene alcohol **36b** (0.086 g, 0.148 mmol) furnished the diene **37b** as a yellow sticky gum (0.045 g, 0.080 mmol, 54%).<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  1.77–1.88 (m, 1H), 1.95–2.10 (m, 1H), 2.20 (dt, *J* = 7.1, 1.5 Hz, 1H), 2.68 (ddd, *J* = 10.2, 7.1, 5.2 Hz, 1H), 3.08–3.13 (m, 1H), 3.70 (s, 3H), 3.81 (s, 3H), 3.85 (s, 3H), 3.86 (s, 3H), 4.63 (dd, *J* = 17.0, 2.0 Hz, 1H), 4.70 (dd, *J* = 10.2, 2.0 Hz, 1H),

4.78 (dt, J = 15.0, 1.4 Hz, 1H), 5.18 (dt, J = 10.2, 1.5 Hz, 1H), 5.18– 5.53 (m, 2H), 5.99 (ddd, J = 17.0, 10.2, 5.5 Hz, 1H), 6.29 (d, J = 1.9 Hz, 1H), 6.41 (dd, J = 8.3, 1.9 Hz, 1H), 6.44 (s, 1H), 6.62 (d, J = 8.3 Hz, 1H), 6.85 (s, 1H), 6.98 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.6 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  39.4, 41.8, 42.6, 46.5, 55.3, 55.7, 55.9, 56.2, 74.6, 100.6, 102.3, 110.7, 112.6, 113.9, 115.4, 115.7, 117.2, 120.5, 126.4, 132.4, 134.5, 134.8, 137.0, 142.9, 147.3, 148.1, 155.0, 155.2, 158.8. IR (UATR):  $\nu_{max}$  2934, 2835, 1513, 1249, 1156, 1029, 832 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 566 (5)  $[C_{31}H_{33}^{-18}BrO_5]^+$ , 564 (4)  $[C_{31}H_{33}^{-7}BrO_5]^+$ , 191 (100). TOF-HRMS: calcd for  $C_{31}H_{33}^{-8}BrNaO_5$  (M + Na<sup>+</sup>) 587.1404, found 587.1379; calcd for  $C_{31}H_{33}^{-8}BrNaO_5$  (M + Na<sup>+</sup>) 589.1389, found 589.1390.

6-Bromo-2-(3,4-dimethoxyphenyl)-3-(1-(3,4dimethoxyphenyl)but-3-en-1-yl)-7-methoxy-4-vinylchroman (37c). Following the general procedure for the BF<sub>3</sub>·Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction at 0 °C for 2 h, diene alcohol 36c (0.030 g, 0.049 mmol) furnished the diene 37c as a yellow sticky gum (0.010 g, 0.017 mmol, 34%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.75-1.86 (m, 1H), 1.99-2.12 (m, 1H), 2.18 (br d, J = 7.1 Hz, 1H), 2.69 (ddd, J = 10.2, 7.1, 5.0 Hz, 1H), 3.06-3.11 (m, 1H), 3.69 (s, 3H), 3.81 (s, 3H), 3.86 (s, 3H), 3.93 (s, 3H), 3.97 (s, 3H), 4.63 (dd, J = 17.0, 2.0 Hz, 1H), 4.71 (dd, J = 10.2, 2.0 Hz, 1H), 4.78 (dt, J = 17.0, 1.4 Hz, 1H), 5.20 (dt, J = 10.2, 1.3 Hz, 1H), 5.22-5.34 (m, 2H), 6.00 (ddd, J = 17.0,10.2, 5.5 Hz, 1H), 6.29 (d, J = 1.9 Hz, 1H), 6.42 (dd, J = 8.2, 1.9 Hz, 1H), 6.47 (s, 1H), 6.63 (d, J = 8.2 Hz, 1H), 6.85 (s, 1H), 6.95 (d, J = 8.2 Hz, 1H), 7.03–7.10 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 39.5, 41.9, 42.5, 46.6, 55.7, 55.8, 55.9, 56.1, 56.2, 74.5, 100.6, 102.3, 108.7, 110.7, 111.2, 112.7, 115.4, 115.7, 117.3, 117.5, 120.4, 132.9, 134.5, 134.8, 137.1, 142.9, 147.4, 148.1, 148.3, 149.2, 155.0, 155.1. IR (UATR):  $\nu_{\rm max}$  2935, 1609, 1514, 1257, 1160, 1142, 1027 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 596 (6)  $[C_{32}H_{35}^{81}BrO_6]^+$ , 594 (3) [C<sub>32</sub>H<sub>35</sub><sup>79</sup>BrO<sub>6</sub>]<sup>+</sup>, 191 (100). TOF-HRMS: calcd for C<sub>32</sub>H<sub>35</sub><sup>79</sup>BrNaO<sub>6</sub>  $(M + Na^{+})$  617.1509, found 617.1500; calcd for  $C_{32}H_{35}^{81}BrNaO_{6}$  (M + Na<sup>+</sup>) 619.1495, found 619.1486.

General Procedure for the Ring-Closing Metathesis. Grubbs II catalyst (10 mol %) or Hoveyda–Grubbs II catalyst (8 mol %) was added to a solution of the corresponding diene (1 equiv) in toluene (100 mL mmol<sup>-1</sup>). Then, the mixture was heated at 60 °C (or 70 °C in the case of Hoveyda–Grubbs II catalyst) for 18 h. The reaction mixture was evaporated under reduced pressure. The residue was purified by PTLC (50/2/48 DCM/MeOH/hexanes) to give the desired cyclic product.

 $(6\beta, 6a\beta, 7\beta, 10a\alpha)$ -2-Bromo-3-methoxy-6,7-bis(4-methoxyphenyl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene (30). Following the general procedure for the ring-closing metathesis using Grubbs II as catalyst (10 mol %), diene 27 (0.013 g, 0.025 mmol) was converted to the corresponding tricyclic product 30, which was obtained as a white sticky gum (0.010 g, 0.020 mmol, 79%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.13-2.25 (m, 1H), 2.65-2.85 (m, 2H), 3.26 (dd, J = 7.0, 3.1 Hz, 1H), 3.64 (s, 6H), 3.78 (s, 3H), 3.80-3.85 (br m, 1H), 5.28 (d, J = 4.4 Hz, 1H), 5.94 (ddt, J = 10.1, 4.8, 2.5 Hz, 1H), 6.31–6.44 (m, 6H), 6.72 (d, J = 8.7 Hz, 2H), 6.77 (d, J = 8.7 Hz, 2H), 7.56 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 28.3, 35.0, 39.4, 42.8, 55.1, 56.1, 81.7, 101.4, 101.7, 112.9, 113.1, 117.9, 127.8, 127.9, 129.4, 130.3, 131.1, 134.7, 153.8, 155.2, 157.6, 159.0. IR (UATR):  $\nu_{max}$  2909, 2835, 1608, 1512, 1247, 1149, 828 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 508 (64)  $[C_{28}H_{27}^{81}BrO_4]^+$ , 506 (66)  $[C_{28}H_{27}^{79}BrO_4]^+$ , 253 (89), 121 (100). TOF-HRMS: calcd for  $C_{28}H_{27}^{-79}BrNaO_4$  (M + Na<sup>+</sup>) 529.0985, found 529.0980; calcd for  $C_{28}H_{27}^{-81}BrNaO_4$  (M + Na<sup>+</sup>) 531.0969, found 531.0949.

(6β,6aβ,7β,10aα)-2-Bromo-7-(3,4-dimethoxyphenyl)-3-methoxy-6-(4-methoxyphenyl)-6a,7,8,10a-tetrahydro-6*H*-benzo-[c]chromene (38b). Following the general procedure for the ringclosing metathesis using Grubbs II as catalyst (10 mol %), diene 37b (0.045 g, 0.080 mmol) was converted to the corresponding tricyclic product 38b, which was obtained as a pale brown sticky gum (0.035 g, 0.065 mmol, 81%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  2.14–2.26 (m, 1H), 2.71 (ddd, *J* = 12.5, 3.9, 3.9 Hz, 1H), 2.73–2.85 (m, 1H), 3.24 (dd, *J* = 7.0, 3.9 Hz, 1H), 3.63, (s, 3H), 3.67 (s, 3H), 3.71 (s, 3H), 3.78 (s, 3H), 3.83–3.92 (m, 1H), 5.28 (d, *J* = 3.9 Hz, 1H), 5.95 (ddt, *J* = 10.1, 4.8, 2.5 Hz, 1H), 6.34–6.46 (m, 7H), 6.73, (d, J = 8.7 Hz, 2H), 7.57 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  28.5, 34.9, 39.7, 42.8, 55.1, 55.6, 55.9, 56.1, 81.6, 101.4, 101.7, 110.8, 112.4, 112.9, 117.9, 121.2, 127.5, 128.0, 129.3, 130.2, 131.0, 135.5, 147.2, 147.9, 153.8, 155.2, 159.0. IR (UATR):  $\nu_{max}$  2932, 2834, 1608, 1513, 1255, 1146, 1028 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 539 (96)  $[C_{29}H_{30}^{81}BrO_5]^+$ , 537 (100)  $[C_{29}H_{30}^{-79}BrO_5]^+$ , 374 (32), 372 (38), 283 (45), 121 (85). TOF-HRMS: calcd for  $C_{29}H_{29}^{-79}BrNaO_5$  (M + Na<sup>+</sup>) 559.1091, found 559.1101; calcd for  $C_{29}H_{29}^{81}BrNaO_5$  (M + Na<sup>+</sup>) 561.1072, found 561.1074.

 $(6\beta, 6a\beta, 7\beta, 10a\alpha)$ -2-Bromo-6,7-bis(3,4-dimethoxyphenyl)-3methoxy-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene (38c). Following the general procedure for the ring-closing metathesis using Grubbs II as catalyst (10 mol %), diene 37c (0.010 g, 0.017 mmol) was converted to the corresponding tricyclic product 38c, which was obtained as a yellow sticky gum (0.008 g, 0.013 mmol, 80%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.16–2.28 (m, 1H), 2.66–2.87 (m, 2H), 3.25 (dd, J = 7.0, 3.1 Hz, 1H), 3.59 (s, 3H), 3.67 (s, 3H),3.71 (s, 3H), 3.72 (s, 3H), 3.79 (s, 3H), 3.90-3.99 (m, 1H), 5.26 (d, J = 4.6 Hz, 1H), 5.97 (ddt, J = 10.2, 4.5, 2.5 Hz, 1H), 6.32-6.50 (m, 8H), 7.58 (d, J = 0.7 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  28.7, 34.9, 39.8, 42.9, 55.67, 55.70, 55.90, 55.95, 56.1, 81.9, 101.5, 101.9, 110.7, 112.2, 112.5, 117.8, 121.2, 121.4, 127.7, 128.1, 130.2, 131.6, 135.5, 147.3, 148.0, 148.1, 148.8, 153.7, 155.3. IR (UATR): ν<sub>max</sub> 2925, 1606, 1516, 1257, 1144, 1026 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 568 (33)  $[C_{30}H_{31}^{81}BrO_{6}]^{+}$ , 566 (36)  $[C_{30}H_{31}^{79}BrO_{6}]^{+}$ , 178 (87), 151 (76), 57(100). TOF-HRMS: calcd for  $C_{30}H_{31}^{79}BrNaO_6$  (M + Na<sup>+</sup>) 589.1196, found 589.1193; calcd for  $C_{30}H_{31}^{-81}BrNaO_6$  (M + Na<sup>+</sup>) 591.1181, found 591.1176.

2-Bromo-3-methoxy-6,7-bis(4-methoxyphenyl)-6a,7,8,10atetrahydro-6*H*-benzo[*c*]chromen-7-ol (31 and 32). Following the general procedure for the ring-closing metathesis using Grubbs II as catalyst (10 mol %), diene alcohol 29 (0.065 g, 0.118 mmol) was converted to the corresponding tricyclic product 31, which was obtained as a brown oil (0.018 g, 0.034 mmol, 29%), and the corresponding tricyclic product 32, which was obtained as a brown oil (0.030 g, 0.057 mmol, 48%).

(6α,6aβ,7β,10aα)-2-Bromo-3-methoxy-6,7-bis(4-methoxyphenyl)-6a,7,8,10a-tetrahydro-6*H*-benzo[c]chromen-7-ol (31). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.81 (br s, 1H), 2.53–2.72 (m, 3H), 3.36 (br d, *J* = 10.7 Hz, 1H), 3.74 (s, 3H), 3.81 (s, 3H), 3.86 (s, 3H), 4.66 (d, *J* = 10.4 Hz, 1H), 6.03–6.13 (m, 1H), 6.30 (dd, *J* = 10.2, 1.9 Hz, 1H), 6.34 (s, 1H), 6.87 (d, *J* = 8.9 Hz, 2H), 7.00 (d, *J* = 8.7 Hz, 2H), 7.34 (d, *J* = 8.9 Hz, 2H), 7.38 (d, *J* = 8.7 Hz, 2H), 7.45 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 36.3, 44.0, 48.9, 55.2, 55.3, 56.2, 74.4, 79.8, 101.1, 102.1, 113.2, 114.3, 118.1, 127.0, 127.2, 128.0, 129.4, 129.8, 132.6, 136.1, 154.1, 154.9, 158.9, 160.2. IR (UATR):  $\nu_{max}$  3563, 2906, 2836, 1609, 1511, 1247 cm<sup>-1</sup>. LRMS (EI): *m/z* (rel intensity) 524 (11) [C<sub>28</sub>H<sub>27</sub><sup>81</sup>BrO<sub>5</sub>]<sup>+</sup>, 522 (11) [C<sub>28</sub>H<sub>28</sub><sup>79</sup>BrO<sub>5</sub>]<sup>+</sup>, 374 (15), 372 (14), 135 (100). TOF-HRMS: calcd for C<sub>28</sub>H<sub>28</sub><sup>81</sup>BrO<sub>5</sub> (M + H<sup>+</sup>) 523.1115, found 523.1090; calcd for C<sub>28</sub>H<sub>28</sub><sup>81</sup>BrO<sub>5</sub> (M + H<sup>+</sup>) 525.1096, found 525.1097.

(6α,6aβ,7α,10aα)-2-Bromo-3-methoxy-6,7-bis(4-methoxyphenyl)-6a,7,8,10a-tetrahydro-6*H*-benzo[c]chromen-7-ol (32). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.15–2.30 (m, 2H), 2.42 (t, *J* = 10.2 Hz, 1H), 2.64–2.77 (m, 1H), 3.67 (s, 3H), 3.69 (s, 3H), 3.69–3.72 (m, 1H), 3.75 (s, 3H), 5.04 (d, *J* = 10.2 Hz, 1H), 5.97 (ddt, *J* = 10.2, 5.0, 2.5 Hz, 1H), 6.38 (s, 1H), 6.39–6.45 (m, 7H), 6.86 (d, *J* = 8.1 Hz, 2H), 7.45 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 34.0, 43.4, 52.5, 55.1, 55.2, 56.3, 72.5, 81.4, 102.6, 102.8, 112.9, 113.2, 123.9, 125.0, 126.2, 126.3, 127.6, 128.1, 134.7, 136.1, 154.8, 155.0, 158.0, 158.3. IR (UATR):  $\nu_{max}$  3503, 2930, 2835, 1608, 1512, 1247 cm<sup>-1</sup>. LRMS (EI): *m/z* (rel intensity) 524 (3) [C<sub>28</sub>H<sub>27</sub><sup>81</sup>BrO<sub>5</sub>]<sup>+</sup>, 522 (3) [C<sub>28</sub>H<sub>27</sub><sup>79</sup>BrO<sub>5</sub>]<sup>+</sup>, 149 (92), 69 (100). TOF-HRMS: calcd for C<sub>28</sub>H<sub>28</sub><sup>81</sup>BrO<sub>5</sub> (M + H<sup>+</sup>) 525.1105, found 523.1094; calcd for C<sub>28</sub>H<sub>28</sub><sup>81</sup>BrO<sub>5</sub> (M + H<sup>+</sup>) 525.1096, found 525.1104.

 $(6\alpha, 6a\beta, 7\beta, 10a\alpha)$ -2-Bromo-3-methoxy-6,7-bis(4-methoxyphenyl)-6a,7,8,10a-tetrahydro-6*H*-benzo[c]chromene (33). Following the general procedure for the BF<sub>3</sub>·Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction at 0 °C for 30 min, tricyclic alcohol 31 (0.014 g, 0.034 mmol) furnished the corresponding tricyclic product **33** as a yellow sticky gum (0.010 g, 0.020 mmol, 58%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  2.18–2.29 (m, 1H), 2.41 (td, J = 10.9, 3.2 Hz, 1H), 2.58–2.75 (m, 1H), 2.95 (dd, J = 7.0, 3.2 Hz, 1H), 3.46 (br d, J = 10.9 Hz, 1H), 3.75 (s, 3H), 3.78 (s, 3H), 3.88 (s, 3H), 4.48 (d, J = 10.9 Hz, 1H), 6.07 (ddd, J = 9.8, 4.3, 2.5 Hz, 1H), 6.29–6.36 (m, 1H), 6.36 (s, 1H), 6.77 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 7.02 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 1.0 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  31.9, 33.1, 36.8, 41.9, 55.2, 55.4, 56.1, 81.1, 101.1, 101.7, 113.3, 114.3, 118.1, 127.7, 128.6, 129.7, 129.8, 130.0, 130.7, 133.9, 154.5, 154.8, 158.4, 160.1. IR (UATR):  $\nu_{max}$  2909, 2830, 1610, 1513, 1250, 1155, 830 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 508 (44) [C<sub>28</sub>H<sub>27</sub><sup>81</sup>BrO<sub>4</sub>]<sup>+</sup>, 506 (37) [C<sub>28</sub>H<sub>27</sub><sup>79</sup>BrNaO<sub>4</sub> (M + Na<sup>+</sup>) 529.0985, found 529.0972; calcd for C<sub>28</sub>H<sub>27</sub><sup>81</sup>BrNaO<sub>4</sub> (M + Na<sup>+</sup>) 531.0969, found 531.0967.

 $(6\alpha, 6a\beta, 7\beta, 10a\beta)$ -2-Bromo-3-methoxy-6,7-bis(4-methoxyphenyl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene (34). Following the general procedure for the BF3·Et2O-mediated Et3SiH reduction at 0 °C for 30 min, tricyclic alcohol 32 (0.052 g, 0.010 mmol) furnished the corresponding tricyclic product 33 (0.009 g, 0.018 mmol, 18%) and the corresponding tricyclic product 34 as a white solid (0.019 g, 0.038 mmol, 38%). Mp (EtOAc/hexanes): 157.3–159.7 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.14–2.27 (m, 1H), 2.40-2.55 (m, 1H), 2.87-2.96 (m, 1H), 3.24-3.33 (m, 1H), 3.70 (s, 3H), 3.71 (s, 3H), 3.76 (s, 3H), 3.76–3.83 (m, 1H), 4.87 (d, J = 10.2 Hz, 1H), 5.76-5.83 (m, 1H), 5.84-5.92 (m, 1H), 6.39 (s, 1H), 6.44 (d, J = 8.7 Hz, 2H), 6.47 (d, J = 8.6 Hz, 2H), 6.56 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 7.39 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>2</sub>):  $\delta$ 24.9, 39.9, 40.4, 42.3, 55.19, 55.21, 56.2, 77.03, 100.9, 102.3, 113.1, 113.2, 119.1, 125.6, 127.5, 129.4, 130.2, 131.1, 132.7, 135.1, 154.9, 155.0, 156.9, 159.4. IR (UATR):  $\nu_{\rm max}$  3001, 2907, 1610, 1514, 1247 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 508 (13)  $[C_{28}H_{27}^{81}BrO_7]^+$ , 506 (12)  $[C_{28}H_{27}^{79}BrO_4]^+$ , 253 (100). TOF-HRMS: calcd for  $C_{28}H_{31}^{79}BrNO_4$  (M + NH<sub>4</sub><sup>+</sup>) 524.1431, found 524.1434; calcd for  $C_{28}H_{31}^{-81}BrNO_4$  (M + NH<sub>4</sub><sup>+</sup>) 526.1415, found 526.1434.

2-Bromo-6-(3,4-dimethoxyphenyl)-3-methoxy-7-(3-methoxyphenyl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-7-ol (39a and 40a). Following the general procedure for the ring-closing metathesis using Grubbs II as catalyst (10 mol %), diene alcohol 36a (0.533 g, 0.917 mmol) was converted to the corresponding tricyclic product 39a, which was obtained as a red sticky gum (0.130 g, 0.238 mmol, 26%), and the corresponding tricyclic product 40a, which was obtained as a yellow sticky gum (0.332 g, 0.596 mmol, 65%).

(6α,6aβ,7β,10aα)-2-Bromo-6-(3,4-dimethoxyphenyl)-3-methoxy-7-(3-methoxyphenyl)-6a,7,8,10a-tetrahydro-6*H*-benzo-[c]chromen-7-ol (39a). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.02 (br s, 1H), 2.55–2.75 (m, 3H), 3.45 (br d, *J* = 10.2 Hz, 1H), 3.75 (s, 3H), 3.80 (s, 3H), 3.92 (s, 3H), 3.93 (s, 3H), 4.66 (d, *J* = 10.2 Hz, 1H), 6.05–6.14 (m, 1H), 6.28–6.36 (m, 1H), 6.36 (s, 1H), 6.81–6.86 (m, 1H), 6.92 (d, *J* = 1.9 Hz, 1H), 6.96 (d, *J* = 8.3 Hz, 1H), 6.99–7.07 (m, 3H), 7.22–7.29 (m, 1H), 7.47 (d, *J* = 0.8 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 36.3, 43.6, 48.8, 55.2, 55.9, 56.0, 56.2, 74.4, 80.2, 101.1, 102.2, 111.3, 111.7, 112.1, 113.0, 118.1, 118.4, 121.0, 126.8, 128.0, 128.8, 129.4, 132.5, 145.9, 149.2, 149.8, 154.0, 154.9, 159.3. IR (UATR):  $\nu_{max}$  3546, 2935, 1607, 1514, 1489, 1260, 1159, 1026 cm<sup>-1</sup>. LRMS (EI): *m*/*z* (rel intensity) 554 (16) [C<sub>29</sub>H<sub>29</sub><sup>81</sup>BrO<sub>6</sub>]<sup>+</sup>, 552 (15) [C<sub>29</sub>H<sub>29</sub><sup>79</sup>BrNaO<sub>6</sub> (M + Na<sup>+</sup>) 575.1024, found 575.1033; calcd for C<sub>29</sub>H<sub>29</sub><sup>81</sup>BrNaO<sub>6</sub> (M + Na<sup>+</sup>) 577.1024, found 577.1016.

(6α,6aβ,7α,10aα)-2-Bromo-6-(3,4-dimethoxyphenyl)-3-methoxy-7-(3-methoxyphenyl)-6a,7,8,10a-tetrahydro-6*H*-benzo-[c]chromen-7-ol (40a). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.17–2.28 (m, 1H), 2.32 (s, 1H), 2.45 (t, J = 10.0 Hz, 1H), 2.66–2.77 (m, 1H), 3.60 (s, 6H), 3.67–3.73 (m, 1H), 3.75 (s, 3H), 3.76 (s, 3H), 5.04 (d, J = 10.0 Hz, 1H), 5.96 (ddt, J = 7.7, 5.0, 2.5 Hz, 1H), 6.10 (d, J = 1.9 Hz, 1H), 6.21 (dd, J = 8.2, 1.9 Hz, 1H), 6.37–6.45 (m, 1H), 6.41 (s, 1H), 6.47 (d, J = 8.2 Hz, 2H), 6.51–6.63 (m, 2H), 6.83 (t, J = 8.2 Hz, 1H), 7.46 (d, J = 0.6 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 33.9, 43.3, 51.9, 54.7, 55.1, 55.7, 56.2, 72.7, 81.5, 102.6, 110.7, 111.2, 111.7, 117.7, 118.8, 123.4, 125.1, 125.9, 127.7, 128.3, 134.8, 145.9, 147.7, 147.8, 154.7, 154.9, 158.7. IR (UATR):  $\nu_{\rm max}$  3503, 2939, 1605, 1487, 1260, 1140, 1026 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 554 (16)  $[C_{29}H_{29}^{81}{\rm BrO_6}]^+$ , 552 (19)  $[C_{29}H_{29}^{79}{\rm BrO_6}]^+$ , 151 (89), 135 (100). TOF-HRMS: calcd for  $C_{29}H_{29}^{79}{\rm BrNaO_6}$  (M + Na<sup>+</sup>) 575.1039, found 575.1028; calcd for  $C_{29}H_{29}^{81}{\rm BrNaO_6}$  (M + Na<sup>+</sup>) 577.1024, found 577.1016.

**2-Bromo-7-(3,4-dimethoxyphenyl)-3-methoxy-6-(4-methoxyphenyl)-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-7-ol (39b and 40b).** Following the general procedure for the ring-closing metathesis using Grubbs II as catalyst (10 mol %), diene alcohol **36b** (0.057 g, 0.103 mmol) was converted to the corresponding tricyclic product **39b**, which was obtained as a yellow oil (0.013 g, 0.024 mmol, 23%), and the corresponding tricyclic product **40b**, which was obtained as a yellow oil (0.028 g, 0.052 mmol, 50%).

(6α,6aβ,7β,10aα)-2-Bromo-7-(3,4-dimethoxyphenyl)-3-methoxy-6-(4-methoxyphenyl)-6a,7,8,10a-tetrahydro-6*H*-benzo-[c]chromen-7-ol (39b). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.82 (br s, 1H), 2.59–2.74 (m, 3H), 3.42 (br d, *J* = 10.5 Hz, 1H), 3.75 (s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 3.89 (s, 3H), 4.69 (d, *J* = 10.5 Hz, 1H), 6.10 (ddd, *J* = 9.9, 6.6, 3.3 Hz, 1H), 6.28–6.35 (m, 1H), 6.35 (s, 1H), 6.83 (d, *J* = 9.0 Hz, 1H), 6.96–7.05 (m, 4H), 7.38 (d, *J* = 8.6 Hz, 2H), 7.46 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 36.4, 44.1, 48.9, 55.4, 55.87, 55.92, 56.2, 74.4, 79.9, 101.2, 102.1, 110.0, 110.5, 114.3, 118.2, 118.3, 126.9, 128.1, 129.4, 129.8, 132.6, 136.8, 148.3, 148.4, 154.1, 155.0, 160.3. IR (UATR):  $\nu_{max}$  3548, 2932, 1609, 1512, 1256 cm<sup>-1</sup>. LRMS (EI): *m/z* (rel intensity) 554 (13) [C<sub>29</sub>H<sub>29</sub><sup>81</sup>BrO<sub>6</sub>]<sup>+</sup>, 552 (14) [C<sub>29</sub>H<sub>29</sub><sup>79</sup>BrO<sub>6</sub>]<sup>+</sup>, 374 (16), 372, (20), 165 (100). TOF-HRMS: calcd for C<sub>29</sub>H<sub>29</sub><sup>81</sup>BrNaO<sub>6</sub> (M + Na<sup>+</sup>) 577.1021, found 577.1025.

(6*α*,6*α*β,7*α*,10*α*α)-2-Bromo-7-(3,4-dimethoxyphenyl)-3-methoxy-6-(4-methoxyphenyl)-6*a*,7,8,10*a*-tetrahydro-6*H*-benzo-[*c*]chromen-7-0l (40b). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.18–2.29 (m, 2H), 2.42 (t, *J* = 10.1 Hz, 1H), 2.67–2.78 (m, 1H), 3.60 (br s, 3H), 3.68 (s, 3H), 3.68–3.74 (m, 1H), 3.758 (s, 3H), 3.764 (s, 3H), 5.05 (d, *J* = 10.1 Hz, 1H), 5.98 (ddt, *J* = 10.2, 5.0, 2.5 Hz, 1H), 6.39 (s, 1H), 6.39–6.49 (m, 7H), 6.60 (br d, *J* = 8.0 Hz, 1H), 7.46 (d, *J* = 0.8 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 34.0, 43.3, 52.8, 55.4, 55.8, 56.3, 72.5, 80.2, 102.7, 102.9, 108.8, 110.4, 113.1, 117.6, 123.9, 125.0, 126.2, 127.5, 128.0, 134.8, 136.7, 147.5, 148.1, 154.8, 155.0, 158.4. IR (UATR):  $ν_{max}$  3503, 2935, 1608, 1514, 1254, 1141 cm<sup>-1</sup>. LRMS (EI): *m*/*z* (rel intensity) 554 (30) [C<sub>29</sub>H<sub>29</sub><sup>31</sup>BrO<sub>6</sub>]<sup>+</sup>, 552 (27) [C<sub>29</sub>H<sub>29</sub><sup>79</sup>BrO<sub>6</sub>]<sup>+</sup>, 165 (100). TOF-HRMS: calcd for C<sub>29</sub>H<sub>29</sub><sup>79</sup>BrO<sub>6</sub> (M + Na<sup>+</sup>) 575.1040, found 575.1040; calcd for C<sub>29</sub>H<sub>29</sub><sup>81</sup>BrO<sub>6</sub> (M + Na<sup>+</sup>) 577.1021, found 577.1005.

2-Bromo-6,7-bis(3,4-dimethoxyphenyl)-3-methoxy-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-7-ol (39c and 40c). Following the general procedure for the ring-closing metathesis using Grubbs II as catalyst (10 mol %), diene alcohol 36c (0.114 g, 0.191 mmol) was converted to the corresponding tricyclic product 39c, which was obtained as a yellow oil (0.038 g, 0.065 mmol, 34%), and the corresponding tricyclic product 40c, which was obtained as a yellow sticky gum (0.067 g, 0.115 mmol, 60%).

(6α,6aβ,7β,10aα)-2-Bromo-6,7-bis(3,4-dimethoxyphenyl)-3methoxy-6a,7,8,10a-tetrahydro-6*H*-benzo[c]chromen-7-ol (39c). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.96 (br s, 1H), 2.55–2.74 (m, 3H), 3.46 (br d, *J* = 10.6 Hz, 1H), 3.76 (s, 3H), 3.86 (s, 3H), 3.89 (s, 3H), 3.91 (s, 3H), 3.93 (s, 3H), 4.68 (d, *J* = 10.6 Hz, 1H), 6.06–6.15 (m, 1H), 6.30–6.37 (m, 1H), 6.37 (s, 1H), 6.83 (d, *J* = 9.0 Hz, 1H), 6.92 (d, *J* = 1.8 Hz, 1H), 6.94 (d, *J* = 8.3 Hz, 1H), 6.97–7.04 (m, 3H), 7.47 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 36.4, 43.9, 48.9, 55.8, 55.9, 56.0, 56.2, 74.2, 80.3, 101.1, 102.1, 110.2, 110.5, 111.1, 111.5, 118.2, 118.4, 121.1, 126.7, 128.2, 129.3, 132.7, 136.8, 148.3, 148.4, 149.3, 149.9, 154.0, 155.0. IR (UATR):  $\nu_{max}$  3510, 2933, 1607, 1512, 1260, 1159, 1026 cm<sup>-1</sup>. LRMS (EI): *m*/*z* (rel intensity) 584 (4) [C<sub>30</sub>H<sub>31</sub><sup>81</sup>BrO<sub>7</sub>]<sup>+</sup>, 582 (4) [C<sub>30</sub>H<sub>31</sub><sup>79</sup>BrO<sub>7</sub>]<sup>+</sup>, 165 (100). TOF-HRMS: calcd for C<sub>30</sub>H<sub>31</sub><sup>79</sup>BrNaO<sub>7</sub> (M + Na<sup>+</sup>) 605.1145, found 605.1143; calcd for C<sub>30</sub>H<sub>31</sub><sup>81</sup>BrNaO<sub>7</sub> (M + Na<sup>+</sup>) 607.1130, found 607.1128.

 $(6\alpha, 6a\beta, 7\alpha, 10a\alpha)$ -2-Bromo-6, 7-bis(3, 4-dimethoxyphenyl)-3methoxy-6a, 7, 8, 10a-tetrahydro-6*H*-benzo[c]chromen-7-ol (40c). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.21 (br s, 1H), 2.19–2.31 (m,

1H), 2.44 (t, J = 10.4 Hz, 1H), 2.68–2.80 (m, 1H), 3.60 (s, 3H), 3.65 (br s, 3H), 3.65–3.71 (m, 1H), 3.76 (s, 3H), 3.77 (s, 6H), 5.03 (d, J = 9.8 Hz, 1H), 5.95–6.03 (m, 1H), 6.02 (d, J = 2.0 Hz, 1H), 6.11 (dd, J = 8.2, 2.0 Hz, 1H), 6.38–6.49 (m, 4H), 6.49–6.60 (br m, 2H), 7.47 (d, J = 0.8 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  33.9, 43.3, 52.8, 55.3, 55.4, 55.8, 55.9, 56.3, 72.4, 81.5, 102.7, 102.8, 108.9, 110.2, 110.3, 110.7, 117.7, 119.1, 123.9, 125.0, 126.2, 127.6, 135.2, 136.8, 147.4, 147.90, 147.95, 148.0, 154.8, 155.0. IR (UATR):  $\nu_{max}$  3506, 2937, 1606, 1516, 1259, 1140, 1026 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 584 (6) [C<sub>30</sub>H<sub>31</sub><sup>81</sup>BrO<sub>7</sub>]<sup>+</sup>, 582 (5) [C<sub>30</sub>H<sub>31</sub><sup>79</sup>BrO<sub>7</sub>]<sup>+</sup>, 165 (100). TOF-HRMS: calcd for C<sub>30</sub>H<sub>31</sub><sup>81</sup>BrNaO<sub>7</sub> (M + Na<sup>+</sup>) 605.1145, found 605.1139; calcd for C<sub>30</sub>H<sub>31</sub><sup>81</sup>BrNaO<sub>7</sub> (M + Na<sup>+</sup>) 607.1130, found 607.1124.

 $(6\alpha, 6a\beta, 7\beta, 10a\alpha)$ -2-Bromo-7-(3,4-dimethoxyphenyl)-3-methoxy-6-(4-methoxyphenyl)-6a,7,8,10a-tetrahydro-6H-benzo-[c]chromene (41b). Following the general procedure for the  $BF_3$ . Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction at -10 to -5 °C for 4 h, tricyclic alcohol 39b (0.015 g, 0.027 mmol) furnished the corresponding tricyclic product 41b as a white sticky gum (0.007 g, 0.014 mmol, 50%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.20–2.33 (m, 1H), 2.44 (td, J = 10.8, 3.2 Hz, 1H), 2.61–2.76 (m, 1H), 2.96 (dd, I = 6.9, 3.2 Hz, 1H), 3.48-3.58 (br m, 1H), 3.75 (s, 3H), 3.78 (s, 3H), 3.85 (s, 3H), 3.87 (s, 3H), 4.52 (d, J = 10.8 Hz, 1H), 6.08 (ddt, J = 10.0, 4.4, 2.4 Hz, 1H), 6.31–6.38 (br m, 1H), 6.36 (s, 1H), 6.54 (d, J = 1.9 Hz, 1H), 6.69 (dd, J = 8.3, 1.9 Hz, 1H), 6.75 (d, J = 8.3 Hz, 1H), 7.02 (d, J = 8.7 Hz, 2H), 7.38 (d, J = 8.7 Hz, 2H), 7.50 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 32.2, 33.1, 37.3, 41.8, 55.4, 55.8, 55.9, 56.2, 81.1, 101.2, 101.8, 110.9, 112.5, 114.3, 118.1, 120.6, 127.6, 128.6, 129.8, 130.1, 130.7, 134.5, 147.9, 148.3, 154.5, 154.9, 160.2. IR (UATR):  $\nu_{\rm max}$  2909, 2835, 1610, 1514, 1250, 1146 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 538 (71)  $[C_{29}H_{29}^{81}BrO_5]^+$ , 536 (59)  $[C_{29}H_{29}^{79}BrO_5]^+$ , 283 (64), 121 (100). TOF-HRMS: calcd for  $C_{29}H_{29}^{79}BrNaO_5$  (M + Na<sup>+</sup>) 559.1091, found 559.1086; calcd for  $C_{29}H_{29}^{81}BrNaO_5$  (M + Na<sup>+</sup>) 561.1075, found 561.1075.

 $(6\alpha, 6a\beta, 7\beta, 10a\alpha)$ -2-Bromo-6,7-bis(3,4-dimethoxyphenyl)-3methoxy-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene (41c). Following the general procedure for the BF3·Et2O-mediated Et3SiH reduction at 0 °C for 18 h, tricyclic alcohol 39c (0.010 g, 0.017 mmol) furnished the corresponding tricyclic product 41c as a yellow oil (0.007 g, 0.012 mmol, 67%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.22-2.32 (m, 1H), 2.43 (td, J = 10.8, 3.2 Hz, 1H), 2.62-2.75 (m, 1H), 2.99 (dd, J = 6.9, 3.2 Hz, 1H), 3.51-3.60 (br m, 1H), 3.76 (s, 3H), 3.77 (s, 3H)3H), 3.85 (s, 3H), 3.92 (s, 3H), 3.95 (s, 3H), 4.51 (d, J = 10.8 Hz, 1H), 6.09 (ddt, J = 9.9, 4.4, 2.4 Hz, 1H), 6.32-6.38 (br m, 1H), 6.38 (s, 1H), 6.56 (d, J = 1.8 Hz, 1H), 6.69 (dd, J = 8.3, 1.8 Hz, 1H), 6.74(d, J = 8.3 Hz, 1H), 6.93 (d, J = 1.8 Hz, 1H), 6.97 (d, J = 8.2 Hz, 1H), 7.25 (dd, J = 8.2, 1.8 Hz, 1H), 7.51 (d, J = 0.9 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 32.2, 33.1, 37.3, 41.8, 55.8, 55.9, 56.0, 56.1, 56.2, 81.5, 101.1, 101.8, 110.8, 111.2, 111.6, 112.7, 118.0, 120.8, 121.7, 127.5, 128.7, 129.7, 130.9, 134.5, 147.9, 148.3, 149.4, 149.7, 154.4, 154.9. IR (UATR):  $\nu_{\text{max}}$  2934, 1608, 1515, 1263, 1157, 1027 cm<sup>-1</sup> LRMS (EI): m/z (rel intensity) 568 (50)  $[C_{30}H_{31}^{81}BrO_6]^+$ , 566 (53)  $[C_{30}H_{31}^{79}BrO_6]^+$ , 313 (61), 151 (100). TOF-HRMS: calcd for  $C_{30}H_{31}^{79}BrNaO_6$  (M + Na<sup>+</sup>) 589.1196, found 589.1181; calcd for  $C_{30}H_{31}^{81}$ BrNaO<sub>6</sub> (M + Na<sup>+</sup>) 591.1181, found 591.1175.

(6*a*,6*a*β,7*β*,10*a*β)-2-Bromo-6-(3,4-dimethoxyphenyl)-3-methoxy-7-(3-methoxyphenyl)-6a,7,8,10a-tetrahydro-6*H*-benzo-[*c*]chromene (42a). Following the general procedure for the BF<sub>3</sub>. Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction at 10 °C for 18 h, tricyclic alcohol 39a (0.028 g, 0.050 mmol) furnished the corresponding tricyclic product 42a as a pale yellow sticky gum (0.005 g, 0.010 mmol, 19%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  2.15–2.27 (m, 1H), 2.46–2.62 (m, 1H), 2.92–3.02 (m, 1H), 3.26–3.36 (m, 1H), 3.58 (s, 3H), 3.67 (s, 3H), 3.77 (s, 3H), 3.82 (s, 3H), 4.86 (d, *J* = 10.2 Hz, 1H), 5.77–5.84 (m, 1H), 5.84–5.93 (m, 1H), 6.14 (s, 1H), 6.30 (d, *J* = 1.8 Hz, 1H), 6.41 (d, *J* = 8.2 Hz, 1H), 6.42 (s, 1H), 6.48 (dd, *J* = 8.2, 2.3 Hz, 1H), 6.59 (d, *J* = 8.1 Hz, 1H), 6.70 (dd, *J* = 8.1, 1.8 Hz, 1H), 6.89 (t, *J* = 8.2 Hz, 1H), 7.40 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  24.4, 40.1, 41.0, 42.6, 54.8, 55.1, 55.7, 56.2, 77.4, 100.9, 102.4, 109.4, 109.9, 110.1, 113.5, 118.9, 119.5, 121.4, 125.5, 128.2, 130.5, 131.2, 132.8, 144.5, 148.4, 149.2, 155.0, 158.8. IR (UATR):  $\nu_{\rm max}$  2923, 2853, 1607, 1443, 1264, 1159, 1050 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 538 (28)  $[C_{29}H_{29}^{81}BrO_5]^+$ , 536 (25)  $[C_{29}H_{29}^{79}BrO_5]^+$ , 283 (100), 151 (37). TOF-HRMS: calcd for  $C_{29}H_{29}^{79}BrNaO_5$  (M + Na<sup>+</sup>) 559.1091, found 559.1103; calcd for  $C_{29}H_{29}^{81}BrNaO_5$  (M + Na<sup>+</sup>) 561.1075, found 561.1092.

 $(6\alpha, 6a\beta, 7\beta, 10a\beta)$ -2-Bromo-7-(3,4-dimethoxyphenyl)-3-methoxy-6-(4-methoxyphenyl)-6a,7,8,10a-tetrahydro-6H-benzo-[c]chromene (42b). Following the general procedure for the  $BF_3$ . Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction at -20 °C for 24 h, tricyclic alcohol 40b (0.023 g, 0.041 mmol) furnished the corresponding tricyclic product 41b (0.004 g, 0.007 mmol, 18%) and the corresponding tricyclic product 42b as a white solid (0.006 g, 0.012 mmol, 27%). Mp (EtOAc/hexanes): 221.5–223.0 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>2</sub>):  $\delta$ 2.16-2.29 (br m, 1H), 2.40-2.54 (br m, 1H), 2.92-3.00 (br m, 1H), 3.71 (s, 3H), 3.72 (s, 3H), 3.76 (s, 3H), 3.79 (s, 3H), 3.80-3.86 (br m, 1H), 4.88 (d, J = 10.2 Hz, 1H), 5.77-5.85 (m, 1H), 5.85-5.93 (m, 1H), 6.18 (dd, J = 8.3, 1.6 Hz, 1H), 6.22 (d, J = 1.6 Hz, 1H), 6.40 (s, 1H), 6.42 (d, J = 8.3 Hz, 1H), 6.49 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 7.40 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 25.0, 40.0, 40.7, 42.5, 55.2, 55.5, 56.0, 56.2, 77.1, 100.9, 102.3, 110.1, 113.2, 118.9, 119.0, 125.5, 129.5, 130.2, 131.2, 132.7, 135.8, 146.5, 148.2, 155.0, 155.1, 159.4. IR (UATR):  $\nu_{\rm max}$  2908, 2835, 1515, 1248, 1158 cm<sup>-1</sup> LRMS (EI): m/z (rel intensity) 538 (26)  $[C_{29}H_{29}^{81}BrO_5]^+$ , 536 (31) [C<sub>29</sub>H<sub>29</sub><sup>79</sup>BrO<sub>5</sub>]<sup>+</sup>, 283 (100). TOF-HRMS: calcd for C<sub>29</sub>H<sub>29</sub><sup>79</sup>BrNaO<sub>5</sub>  $(M + Na^{+})$  559.1091, found 559.1096; calcd for  $C_{29}H_{29}^{81}BrNaO_5$  (M + Na<sup>+</sup>) 561.1075, found 561.1075.

 $(6\alpha, 6a\beta, 7\beta, 10a\beta)$ -2-Bromo-6,7-bis(3,4-dimethoxyphenyl)-3methoxy-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene (42c). Following the general procedure for the BF3·Et2O-mediated Et3SiH reduction at 20 °C for 18 h, tricyclic alcohol 40c (0.067 g, 0.115 mmol) furnished the corresponding tricyclic product 42c as a yellow sticky gum (0.024 g, 0.043 mmol, 37%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.18-2.29 (br m, 1H), 2.43-2.59 (br m, 1H), 2.70-2.98 (br m, 1H), 3.26-3.36 (br m, 1H), 3.64 (s, 3H), 3.73 (s, 3H), 3.77 (s, 3H), 3.78 (s, 3H), 3.81 (s, 3H), 4.87 (d, J = 10.2 Hz, 1H), 5.77-5.85 (m, 1H), 5.85–5.94 (m, 1H), 6.16 (dd, J = 8.0, 1.6 Hz, 1H), 6.30 (d, J = 1.6 Hz, 1H), 6.37 (d, J = 1.8 Hz, 1H), 6.40 (d, J = 8.0 Hz, 1H), 6.41 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.63 (dd, J = 8.1, 1.8 Hz, 1H), 7.40 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  24.8, 40.0, 40.8, 42.6, 55.3, 55.5, 55.9, 56.1, 56.2, 100.9, 102.4, 110.3, 110.4, 110.8, 118.8, 118.9, 121.3, 125.6, 130.7, 131.2, 132.7, 135.8, 146.6, 148.2, 148.5, 149.1, 155.0. IR (UATR):  $\nu_{\text{max}}$  2926, 1613, 1504, 1263, 1155, 1029 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 568 (24)  $[C_{30}H_{31}^{81}BrO_6]^+$ , 566 (21)  $[C_{30}H_{31}^{79}BrO_6]^+$ , 313 (100), 175 (30), 151 (27). TOF-HRMS: calcd for  $C_{30}H_{31}^{79}BrNaO_6$  (M + Na<sup>+</sup>) 589.1196, found 589.1194; calcd for  $C_{30}H_{31}^{81}BrNaO_6$  (M + Na<sup>+</sup>) 591.1181, found 591.1179.

 $(6\alpha, 6a\alpha, 7\beta, 10a\beta)$ -2-Bromo-6-(3,4-dimethoxyphenyl)-3-methoxy-7-(3-methoxyphenyl)-6a,7,8,10a-tetrahydro-6H-benzo-[c]chromen-7-ol (43). Following the general procedure for the  $BF_3$ · Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction at 0 °C for 18 h, tricyclic alcohol 40a (0.069 g, 0.125 mmol) furnished the corresponding tricyclic product 42a (0.010 g, 0.019 mmol, 15%) and the corresponding tricyclic alcohol 43 as a pale yellow oil (0.013 g, 0.024 mmol, 19%). <sup>1</sup>H NMR (300 MHz,  $CDCl_3$ ):  $\delta$  1.34 (d, J = 2.1 Hz, 1H), 2.17–2.29 (m, 1H), 2.39-2.51 (m, 1H), 2.94 (dd, J = 4.3 Hz, 1H), 3.64 (s, 3H), 3.82 (s, 3H), 3.84 (s, 3H), 3.85 (s, 3H), 3.86-3.92 (m, 1H), 5.30 (d, J = 4.3 Hz, 1H), 5.80 (ddt, J = 10.1, 4.8, 2.5 Hz, 1H), 6.19 (d, J = 2.0 Hz, 1H), 6.34 (br d, J = 10.1 Hz, 1H), 6.46 (s, 1H), 6.48 (dd, J = 8.4, 2.0 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 6.89 (dd, J = 8.1, 2.7 Hz, 1H), 7.04-7.12 (m, 2H), 7.39 (t, J = 8.1 Hz, 1H), 7.60 (d, J = 0.8 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 28.4, 44.1, 45.4, 55.3, 55.6, 55.9, 56.2, 73.3, 76.5, 100.9, 102.1, 110.8, 111.5, 111.8, 112.0, 117.5, 117.6, 119.6, 125.6, 125.8, 129.9, 130.1, 131.5, 148.0, 148.8, 149.3, 153.8, 155.4, 160.0. IR (UATR):  $\nu_{\rm max}$  3545, 2923, 1607, 1442, 1259, 1147, 1025 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 554 (13)  $[C_{29}H_{29}^{81}BrO_6]^+$ , 552 (10)  $[C_{29}H_{29}^{-79}BrO_6]^+$ , 151 (100), 135 (95). TOF-HRMS: calcd for  $C_{29}H_{29}{}^{79}BrNaO_6~(M + Na^+)$ 575.1039, found 575.104 $C_{29}H_{29}{}^{81}BrNaO_6~(M + Na^+)$ 577.1024, found 577.1021.  $^{'9}$ BrNaO<sub>6</sub> (M + Na<sup>+</sup>) 575.1039, found 575.1042; calcd for

1-(6-Bromo-7-methoxy-2-(4-methoxyphenyl)-4-vinylchroman-3-yl)-1-(4-methoxyphenyl)-3-methylbut-3-en-1-ol (44). Following the general procedure for the Lindlar hydrogenation and allyl Grignard addition (while using methallyl Grignard instead), ketone alkyne 28 (0.170 g, 0.335 mmol) was converted to the corresponding diene alcohol 44, which was obtained as a 1.4:1 inseparable mixture of diastereomers as a white sticky gum (0.142 g, 0.251 mmol, 75%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.31 (s, 3H), 2.54 (s, 1H, minor), 2.56 (s, 1H, major), 2.58-2.71 (m, 2H), 2.75-2.83 (m, 1H, minor), 2.88-2.96 (m 1H, major), 3.46 (d, I = 8.3 Hz, 1H, minor), 3.73 (s, 3H), 3.76 (s, 3H, minor), 3.80 (s, 6H, major), 3.86 (s, 3H, minor), 3.87 (s, 3H, major), 4.48-4.59 (m, 2H, minor), 4.64-4.73 (m, 2H), 4.78-4.88 (m, 2H), 5.02-5.21 (m, 1H), 5.23 (s, 1H), 5.68 (s, 1H, minor), 6.50 (s, 1H, minor), 6.55 (s, 1H, major), 6.71 (d, J = 8.8 Hz, 2H, major), 6.78 (d, J = 8.7 Hz, 2H, minor), 6.83 (d, J = 8.8 Hz, 2H, minor), 6.87 (d, J = 8.8 Hz, 2H, major), 6.93 (d, J = 8.8 Hz, 2H, major), 7.06 (d, J = 8.8 Hz, minor), 7.07 (s, 1H, minor), 7.18 (s, 1H, major), 7.31 (d, J = 8.7 Hz, 2H, minor), 7.38 (d, J = 8.8 Hz, 2H, major). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 24.2 (major), 24.4 (minor), 37.8 (major), 38.3 (minor), 46.6 (minor), 47.2 (major), 54.3 (major), 55.0 (minor), 55.1 (major), 56.1 (major), 74.8 (major), 75.0 (minor), 77.5 (minor), 78.2 (major), 100.8 (major), 102.56 (major), 102.62 (minor), 113.0 (minor), 113.39 (major), 113.44 (major), 113.7 (minor), 113.8 (major), 116.1 (major), 116.2 (minor), 118.0 (major), 118.5 (minor), 126.7 (major), 127.0 (major), 127.1 (minor), 127.4 (minor), 133.3 (minor), 133.50 (minor), 133.54 (major), 133.6 (minor), 136.2 (minor), 136.8 (major), 141.8 (major), 141.88 (minor), 141.91 (minor), 142.1(major), 153.2 (major), 153.5 (minor), 155.0 (minor), 155.1 (major), 158.2 (major), 158.3 (major), 158.38 (minor), 158.42 (minor). IR (UATR):  $\nu_{\rm max}$  3526, 2934, 1610, 1510, 1248 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 566 (0.4)  $[C_{31}H_{33}^{81}BrO_5]^+$ , 564 (0.4)  $[C_{31}H_{33}^{79}BrO_5]^+$ , 376 (3), 374 (3), 135 (100), 121 (16). TOF-HRMS: calcd for  $C_{31}H_{33}^{79}BrNaO_5$  (M + Na<sup>+</sup>) 587.1404, found 587.1408; calcd for  $C_{31}H_{35}^{81}BrNaO_5$  (M + Na<sup>+</sup>) 589.1385, found 589.1383.

**2-Bromo-3-methoxy-6,7-bis(4-methoxyphenyl)-9-methyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-7-ol (45).** Following the general procedure for the ring-closing metathesis using Hoveyda– Grubbs II catalyst (8 mol %) at 70 °C, diene alcohol 44 (0.370 g, 0.650 mmol) furnished the corresponding tricyclic alcohol 45 as a pale yellow sticky gum (0.123 g, 0.227 mmol, 35%) and 46 as a pale yellow sticky gum (0.132 g, 0.247 mmol, 38%).

(6α,6aβ,7β,10aα)-2-Bromo-3-methoxy-6,7-bis(4-methoxyphenyl)-9-methyl-6a,7,8,10a-tetrahydro-6*H*-benzo[c]chromen-7-ol (45). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.80 (br s, 1H), 1.89 (br s, 3H), 2.41–2.61 (m, 3H), 3.27 (br d, *J* = 10.6 Hz, 1H), 3.74 (s, 3H), 3.82 (s, 3H), 3.86 (s, 3H), 4.65 (d, *J* = 10.6 Hz, 1H), 6.01 (br s, 1H), 6.34 (s, 1H), 6.87 (d, *J* = 8.7 Hz, 2H), 7.00 (d, *J* = 8.7 Hz, 2H), 7.27 (d, *J* = 8.7 Hz, 2H), 7.37 (d, *J* = 8.7 Hz, 2H), 7.46 (s, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 23.0, 36.2, 48.6, 48.9, 55.2, 55.3, 56.1, 74.6, 79.8, 101.1, 102.0, 113.2, 114.3, 118.7, 121.2, 127.2, 129.4, 129.7, 132.6, 135.7, 136.2, 154.0, 154.8, 158.9, 160.2. IR (UATR):  $\nu_{max}$  3557, 2907, 2836, 1609, 1512, 1247, 1161, 1033, 831 cm<sup>-1</sup>. LRMS (EI): *m/z* (rel intensity) 538 (5)  $[C_{29}H_{29}^{81}BrO_5]^+$ , 536 (5)  $[C_{29}H_{29}^{79}BrN_6]^+$ , 388 (16), 136 (17), 135 (100). TOF-HRMS: calcd for  $C_{29}H_{29}^{81}BrO_5$  (M + Na<sup>+</sup>) 559.1091, found 559.1073; calcd for  $C_{29}H_{29}^{81}BrO_5$  (M + Na<sup>+</sup>) 561.1075, found 561.1063.

(6α,6aβ,7α,10aα)-2-Bromo-3-methoxy-6,7-bis(4-methoxyphenyl)-9-methyl-6a,7,8,10a-tetrahydro-6*H*-benzo[c]chromen-7-ol (46). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.60 (br s, 1H), 1.84 (br s, 3H), 2.09 (br d, *J* = 18.5 Hz, 1H), 2.35 (t, *J* = 10.2 Hz, 1H), 2.66 (br d, *J* = 18.5 Hz, 1H), 3.60–3.65 (m, 1H), 3.65 (s, 3H), 3.69 (s, 3H), 3.76 (s, 3H), 5.04 (d, *J* = 10.2 Hz, 1H), 6.11 (br s, 1H), 6.38 (s, 1H), 6.39– 6.46 (m, 6H), 6.87 (br d, *J* = 8.1 Hz, 2H), 7.46 (d, *J* = 0.9 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 23.5, 34.0, 48.2, 52.3, 55.10, 55.13, 56.2, 72.9, 81.4, 102.5, 102.7, 112.8, 113.2, 118.7, 124.2, 126.2, 127.5, 128.1, 133.9, 134.7, 136.0, 154.8, 154.9, 157.9, 158.3. IR (UATR):  $\nu_{max}$  3503, 2909, 2835, 1608, 1512, 1247, 1178, 825 cm<sup>-1</sup>. LRMS (EI): *m/z* (rel intensity) 538 (8) [C<sub>29</sub>H<sub>29</sub><sup>81</sup>BrO<sub>5</sub>]<sup>+</sup>, 536 (8) [C<sub>29</sub>H<sub>29</sub><sup>79</sup>BrO<sub>5</sub>]<sup>+</sup>, 135 (100). TOF-HRMS: calcd for C<sub>29</sub>H<sub>29</sub><sup>79</sup>BrNaO<sub>5</sub> (M + Na<sup>+</sup>) 559.1091, found 559.1092; calcd for  $\rm C_{29}H_{29}{}^{81}BrNaO_{5}~(M$  + Na^+) 561.1075, found 561.1075.

 $(6\alpha, 6a\beta, 7\beta, 10a\alpha)$ -2-Bromo-3-methoxy-6,7-bis(4-methoxyphenyl)-9-methyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromene (47). Following the general procedure for the BF<sub>3</sub>·Et<sub>2</sub>Omediated Et<sub>3</sub>SiH reduction at -20 °C for 3.5 h, tricyclic alcohol 45 (0.023 g, 0.043 mmol) furnished the corresponding tricyclic alcohol 47 as a white sticky gum (0.019 g, 0.036 mmol, 84%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  1.86 (br s, 3H), 2.07 (br d, J = 18.2 Hz, 1H), 2.33 (td, J = 10.9, 3.2 Hz, 1H), 2.61 (br d, J = 18.2 Hz, 1H), 2.95 (dd, J = 6.9, 3.2 Hz, 1H), 3.46 (br d, J = 10.9 Hz, 1H), 3.74 (s, 3H), 3.78 (s, 3H), 3.88 (s, 3H), 4.48 (d, J = 10.9 Hz, 1H), 6.04 (br s, 1H), 6.35 (s, 1H), 6.76 (d, J = 8.7 Hz, 2H), 6.93 (d, J = 8.7 Hz, 2H), 7.02 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.50 (d, J = 0.8 HZ, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 23.7, 32.0, 37.3, 37.8, 42.1, 55.2, 55.4, 56.1, 81.1, 101.0, 101.6, 113.3, 114.3, 118.6, 121.9, 129.7, 130.0, 130.9, 134.0, 154.0, 154.4, 154.7, 158.4, 160.1. IR (UATR): ν<sub>max</sub> 2907, 2835, 1610, 1511, 1247, 1158 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 522 (31)  $[C_{29}H_{29}^{81}BrO_4]^+$ , 520 (27)  $[C_{29}H_{29}^{79}BrO_4]^+$ , 253 (100), 121 (58). TOF-HRMS: calcd for  $C_{29}H_{30}^{79}BrO_4$  (M + H<sup>+</sup>) 521.1322, found 521.1313; calcd for  $C_{29}H_{30}^{81}BrO_4$  (M + H<sup>+</sup>) 523.1306, found 523,1313

 $(6\alpha, 6a\alpha, 7\beta, 10a\beta)$ -2-Bromo-3-methoxy-6,7-bis(4-methoxyphenyl)-9-methyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-7-ol (48). Following the general procedure for the BF<sub>3</sub> Et<sub>2</sub>O-mediated Et<sub>3</sub>SiH reduction at 10 °C for 1.5 h, tricyclic alcohol 46 (0.060 g, 0.110 mmol) furnished the corresponding tricyclic product 47 (0.020 g, 0.039 mmol, 35%) and the corresponding tricyclic alcohol 48 as a white sticky gum (0.013 g, 0.024 mmol, 22%). <sup>1</sup>H NMR (300 MHz,  $CDCl_3$ :  $\delta$  1.20 (d, J = 2.2 Hz, 1H), 1.73 (br s, 3H), 2.06 (br d, J =18.2 Hz, 1H), 2.37 (br d, J = 18.2 Hz, 1H), 2.83 (dd, J = 11.7, 4.3 Hz, 1H), 3.75 (s, 3H), 3.75-3.80 (m, 1H), 3.80 (s, 3H), 3.88 (s, 3H), 5.28 (d, I = 4.3 Hz, 1H), 6.03 (br s, 1H), 6.44 (s, 1H), 6.68-6.77 (m, 4H),6.99 (d, J = 8.7 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 7.61 (d, J = 0.8 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  23.3, 28.3, 45.4, 49.1, 55.25, 55.33, 56.2, 73.4, 76.5, 100.9, 102.0, 114.0, 114.1, 118.2, 119.7, 126.3, 128.7, 130.1, 131.2, 133.3, 138.1, 153.9, 155.3, 158.7, 159.9. IR (UATR):  $\nu_{\rm max}$  3552, 2933, 2836, 1609, 1511, 1248 cm<sup>-1</sup>. LRMS (EI): m/z (rel intensity) 538 (2)  $[C_{29}H_{29}^{81}BrO_5]^+$ , 536 (1)  $[C_{29}H_{29}^{79}BrO_5]^+$ , 388 (16), 386 (17), 135 (100). TOF-HRMS: calcd for  $C_{29}H_{29}^{79}BrNaO_5$  (M + Na<sup>+</sup>) 559.1091, found 559.1085; calcd for  $C_{29}H_{29}^{81}BrNaO_5$  (M + Na<sup>+</sup>) 561.1075, found 561.1096.

## ASSOCIATED CONTENT

#### **S** Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b03086.

<sup>1</sup>H and <sup>13</sup>C NMR spectra for all new compounds, NOE results of compounds **27**, **30–34**, and **48** and discussion of the assignment of stereochemistry (PDF)

#### AUTHOR INFORMATION

#### **Corresponding Author**

\*E-mail for P.P.: poonsakdi@cri.or.th.

#### ORCID 🔍

Poonsakdi Ploypradith: 0000-0003-2893-1598

#### Notes

The authors declare no competing financial interest.

#### ACKNOWLEDGMENTS

Financial support from the Thailand Research Fund (BRG5980010 and IRN58W0005) and Mahidol University is gratefully acknowledged.

#### REFERENCES

(1) Lin, C.-N.; Lu, C.-M. Tetrahedron Lett. 1993, 34, 8249-8250.

(2) Skrabek, R. Q.; Galimova, L.; Ethans, K.; Perry, D. J. J. Pain 2008, 9, 164-173.

(3) Wu, T.-S.; Wang, M.-L.; Wu, P.-L. Tetrahedron Lett. 1995, 36, 5385-5388.

(4) (a) Muhammad, I.; Li, X.-C.; Dunbar, D. C.; ElSohly, M. A.; Khan, I. A. J. Nat. Prod. 2001, 64, 1322-1325. (b) Muhammad, I.; Li, X.-C.; Jacob, M. R.; Tekwani, B. L.; Dunbar, D. C.; Ferreira, D. J. Nat.

Prod. 2003, 66, 804-809. (5) Sung, S. H.; Kim, Y. C. J. Nat. Prod. 2000, 63, 1019-1021.

(6) Minagawa, K.; Kouzuki, S.; Nomura, K.; Yamaguchi, T.; Kawamura, Y.; Matsushima, K.; Tani, H.; Ishii, K.; Tanimoto, T.; Kamigauchi, T. J. Antibiot. 2001, 54, 890-895.

(7) Gonzalez, J. G.; Olivares, E. M.; Monache, F. D. Phytochemistry 1995, 38, 485-489.

(8) Appendino, G.; Gibbons, S.; Giana, A.; Pagani, A.; Grassi, G.; Stavri, M.; Smith, E.; Rahman, M. M. J. Nat. Prod. 2008, 71, 1427-1430

(9) (a) Garrido, L.; Zubía, E.; Ortega, M. J.; Salvá, J. J. Nat. Prod. 2002, 65, 1328-1331. (b) Simon-Levert, A.; Arrault, A.; Bontemps-Subielos, N.; Canal, C.; Banaigs, B. J. Nat. Prod. 2005, 68, 1412-1415. (c) Carroll, A. R.; Bowden, B. F.; Coll, J. C. Aust. J. Chem. 1993, 46, 1079 - 1083.

(10) Shirota, O.; Takizawa, K.; Sekita, S.; Satake, M. J. Nat. Prod. 1997, 60, 997-1002.

(11) (a) Chittiboyina, A. G.; Reddy, C. R.; Watkins, E. B.; Avery, M. A. Tetrahedron Lett. 2004, 45, 1689-1691. (b) Huang, Q.; Wang, Q.; Zheng, J.; Zhang, J.; Pan, X.; She, X. Tetrahedron 2007, 63, 1014-1021. (c) Xia, L.; Lee, Y. R. Synlett 2008, 2008, 1643-1646. (d) Wang, Q.; Huang, Q.; Chen, B. O.; Lu, J.; Wang, H.; She, X.; Pan, X. Angew. Chem., Int. Ed. 2006, 45, 3651-3653. (e) Lee, H. J.; Lee, Y. R.; Kim, S. H. Helv. Chim. Acta 2009, 92, 1404-1412.

(12) (a) Huffman, J. W.; Joyner, H. H.; Lee, M. D.; Jordan, R. D.; Pennington, W. T. J. Org. Chem. 1991, 56, 2081-2086. (b) Archer, R. A.; Blanchard, W. B.; Day, W. A.; Johnson, D. W.; Lavagnino, E. R.; Ryan, C. W.; Baldwin, J. E. J. Org. Chem. 1977, 42, 2277-2284.

(13) Hong, B.-C.; Kotame, P.; Tsai, C.-W.; Liao, J.-H. Org. Lett. 2010, 12, 776-779.

(14) (a) Mechoulam, R.; Braun, P.; Gaoni, Y. J. Am. Chem. Soc. 1972, 94, 6159-6165 and references cited therein. (b) Fahrenholtz, K. E.; Lurie, M.; Kierstead, R. W. J. Am. Chem. Soc. 1967, 89, 5934-5941 and references cited therein. (c) Chan, T. H.; Chaly, T. Tetrahedron Lett. 1982, 23, 2935-2938. (d) Rickards, R. W.; Roenneberg, H. J. Org. Chem. 1984, 49, 572-573. (e) Childers, W. E.; Pinnick, H. W. J. Org. Chem. 1984, 49, 5276-5277. (f) Evans, D. A.; Barnes, D. M.; Johnson, J. S.; Lectka, T.; Matt, P. V.; Miller, S. J.; Murry, J. A.; Norcross, R. D.; Shaughnessy, E. A.; Campos, K. R. J. Am. Chem. Soc. 1999, 121, 7582-7594 and references cited therein. (g) William, A. D.; Kobayashi, Y. J. Org. Chem. 2002, 67, 8771-8782 and references cited therein. (h) Trost, B. M.; Dogra, K. Org. Lett. 2007, 9, 861-864. (i) Pearson, E. L.; Kanizaj, N.; Willis, A. C.; Paddon-Row, M. N.; Sherburn, M. S. Chem. - Eur. J. 2010, 16, 8280-8284. (j) Cheng, L.-J.; Xie, J.-H.; Chen, Y.; Wang, L.-X.; Zhou, Q.-L. Org. Lett. 2013, 15, 764-767. (k) Schafroth, M. A.; Zuccarello, G.; Krautwald, S.; Sarlah, D.; Carreira, E. M. Angew. Chem., Int. Ed. 2014, 53, 13898-13901.

(15) (a) Minuti, L.; Ballerini, E. J. Org. Chem. 2011, 76, 5392-5403. (b) Geng, Z.-C.; Zhang, S.-Y.; Li, N.-K.; Li, N.; Chen, J.; Li, H.-Y.; Wang, X.-W. J. Org. Chem. 2014, 79, 10772-10785. (c) Minuti, L.; Ballerini, E.; Barattucci, A.; Bonaccorsi, P. M.; Di Gioia, M. L.; Leggio, A.; Siciliano, C.; Temperini, A. Tetrahedron 2015, 71, 3253-3262.

(16) (a) Batsomboon, P.; Phakhodee, W.; Ruchirawat, S.; Ploypradith, P. J. Org. Chem. 2009, 74, 4009-4012. (b) Tummatorn, J.; Ruchirawat, S.; Ploypradith, P. Chem. - Eur. J. 2010, 16, 1445-1448. (c) Radomkit, S.; Sarnpitak, P.; Tummatorn, J.; Batsomboon, P.; Ruchirawat, S.; Ploypradith, P. Tetrahedron 2011, 67, 3904-3914. (d) Tangdenpaisal, K.; Chuayboonsong, K.; Sukjarean, P.; Katesampao, V.; Noiphrom, N.; Ruchirawat, S.; Ploypradith, P. Chem. - Asian J. 2015, 10, 1050-1064.

(17) An aldol reaction between benzadehyde 10 and a styrene ketone similar to 11 but without the Ar group at the allylic position was

successful, giving the corresponding product in 65% yield. See ref 16b for more details.

(18) A similar approach for the synthesis of  $\Delta^9$ -THC utilizing RCM as a key step for the formation of the fused cyclohexene ring was reported. For more detail, see ref 14k. For a discussion on RCM, see: (a) Kürti, L.; Czako, B. Strategic Applications of Named Reactions in Organic Synthesis; Elsevier: Amsterdam, 2005; pp 10-12 and references cited therein (pp 534-536). (b) Hoveyda, A. J. Org. Chem. 2014, 79, 4763-4792. For recent examples utilizing RCM as a key step in the total synthesis of six-membered carbocycle-containing or six-membered carbocycle-derived products, see: (c) Blanchard, N.; Eustache, J. Synthesis of Natural Products Containing Medium-size Carbocycles by Ring-closing Alkene Metathesis. In Metathesis in Natural Product Synthesis: Strategies, Substrates and Catalysts; Cossy, J., Arseniyadis, S., Meyer, C., Eds.; Wiley-VCH: Weinheim, Germany, 2010; pp 1-44 and references cited therein. (d) Finnegan, D. F.; Snapper, M. L. J. Org. Chem. 2011, 76, 3644-3653. (e) Donohoe, T. J.; Jones, C. R.; Kornahrens, A. F.; Barbosa, L. C. A.; Walport, L. J.; Tatton, M. R.; O'Hagan, M.; Rathi, A. H.; Baker, D. B. J. Org. Chem. 2013, 78, 12338-12350. (f) Schmidt, B.; Hauke, S.; Mühlenberg, N. Synthesis 2014, 46, 1648-1658. (g) Schmidt, B.; Audörsch, S. Org. Lett. 2016, 18, 1162-1165.

(19) An allylic alcohol similar to that from the vinyl Grignard reaction of 10 could be employed in an  ${Ir(cod)Cl}_2/{Zn(OTf)}_2$  dual catalytic  $\alpha$ -allylation with an aldehyde. For more details, see ref 14k.

(20) Yang, B.-L.; Tian, S.-K. Chem. Commun. 2010, 46, 6180-6182. (21) (a) Kruse, L. I.; Kaiser, C.; DeWolf, W. E., Jr.; Chambers, P. A.; Goodhart, P. J.; Ezekiel, M.; Ohlstein, E. H. J. Med. Chem. 1988, 31, 704-706. (b) Kennedy-Smith, J. J.; Young, L. A.; Toste, F. D. Org. Lett. 2004, 6, 1325-1327.

(22) The relative stereochemistry as 2,4-cis and 2,4-trans was established on the basis of our previous findings. See ref 16 for more detailed discussions.

(23) From the reaction, peaks on the  ${}^1\!\mathrm{H}$  NMR could be clearly interpreted to be in accordance with the structure of the chroman ketone 22. Unfortunately, purification of 22 from the remaining amount of the (E)-chalcone proved to be difficult; it was not possible to obtain 22 in a spectroscopically pure form. Thus, the exact yield of 22 could not be determined. In addition, when other  $\alpha_{\beta}$ -unsaturated ketones (alkyl substituted as well as (E)-1-phenylhexa-1,5-dien-3-one (PhCH=CHCOCH<sub>2</sub>CH=CH<sub>2</sub>)) were employed in the PtCl<sub>4</sub>catalyzed cycloaddition reactions with either 14 or 15, no corresponding desired products could be obtained. Only decomposition of 14 or 15 was observed with complete recovery of the  $\alpha_{\beta}$ unsaturated ketones.

(24) This is in agreement with our previous findings of different reaction modes of quinone methides. For chalcones containing 3,5dimethoxyphenyl group(s), the corresponding diarylmethane(s) could be isolated as the product(s) from the reaction(s) between the quinone methide and these electron-rich aromatics. For more details, see: Tangdenpaisal, K.; Phakhodee, W.; Ruchirawat, S.; Ploypradith, P. Tetrahedron 2013, 69, 933-941.

(25) See the Supporting Information for a more detailed stereochemical assignment and discussion.

(26) (a) Trillo, P.; Baeza, A.; Nájera, C. Eur. J. Org. Chem. 2012, 2012, 2929-2934. (b) Yamasaki, S.; Fujii, K.; Wada, R.; Kanai, M.; Shibasaki, M. J. Am. Chem. Soc. 2002, 124, 6536-6537.

(27) (a) Yazaki, R.; Kumagai, N.; Shibasaki, M. Org. Lett. 2011, 13, 952-955. (b) Yazaki, R.; Kumagai, N.; Shibasaki, M. Chem. - Asian J. 2011, 6, 1778-1790.

(28) Other hydrogenation reaction conditions under a lower pressure of hydrogen required longer reaction times. No reaction was observed when pyridine or quinoline was present in the reaction mixtures.

(29) The  $Et_2O/THF$  mixed solvent system was necessary due to the low solubility of the starting material ketone alkene in Et<sub>2</sub>O. In addition, performing the reaction using only THF as solvent gave the product in low yield. It is also critical to perform the reaction at 10 °C for 18 h; other temperatures and durations for the reaction gave much lower yields of the product.

(30) (a) Orfanopoulos, M.; Smonou, I. Synth. Commun. 1988, 18, 833–839. (b) Tagat, J. R.; Guzi, T. J.; Labroli, M.; Poker, C.; Xiao, Y.; Kerekes, A. D.; Yu, T.; Paliwal, S.; Tsui, H.-C.; Shih, N.-Y.; McCombie, S. W.; Madison, V. S.; Lesburg, C. A.; Duca, J. S. Patent WO2006098961, 2006. (c) Larson, G. L.; Fry, J. L. Org. React. 2008, 1–737. High diastereoselectivity could be obtained from this type of reaction; see: (d) Carey, F. A.; Tremper, H. S. J. Org. Chem. 1969, 34, 4–6.

(31) Various conditions using different Lewis acids and hydride sources were investigated for different reaction times and temperatures including the amounts of the Lewis acids and the hydride sources. It is critical to optimize the reaction conditions for each substrate.

(32) Hong, S. H.; Sanders, D. P.; Lee, C. W.; Grubbs, R. H. J. Am. Chem. Soc. 2005, 127, 17160-17161.

(33) The relative stereochemistry of the hydroxy group at C7 of both 31 and 32 was established on the basis of the NOE experiments. For 31, NOE enhancement (2%) was observed between the  $\beta$ -proton at position 6a and the tertiary hydroxy proton. For 32, no such enhancement could be detected. Thus, compound 31 was assigned as the 7 $\beta$ -OH and 32 as the 7 $\alpha$ -OH diastereomer, respectively. While the use of NOE for this particular spectroscopic purpose has not been reported for tertiary alcohols, there have been examples where NOE or 2D-NOESY was employed to establish the regiochemistry of the oxindole: Pavlovskaya, T. L.; Yaremenko, F. G.; Lipson, V. V.; Shishkina, S. V.; Shishkin, O. V.; Musatov, V. I.; Karpenko, A. S. Beilstein J. Org. Chem. 2014, 10, 117-126. NOE or 2D-NOESY was also employed to establish the regiochemistry of the hydrazine on the pyrimidine ring: Hutchinson, D. J.; Hanton, L. R.; Moratti, S. C. Dalton Trans. 2014, 43, 8205-8218. In both cases, the protons on the heteroatom (N) were irradiated and showed the positive NOE values with the adjacent aromatic protons. In our case, the tertiary hydroxy proton of 31 appears as a sharp singlet and does not interchange with deuterium appreciably. Thus, it is possible to irradiate this tertiary hydroxy proton specifically to observe any enhancement this may cause on other protons. See the Supporting Information for more details.

(34) The stereochemical assignment of all intermediates and final products followed that of 27-34.

(35) For compounds 43 and 48, the relative stereochemistry was also established on the basis of the NOE enhancements (or the lack thereof) and the coupling constants (J values) of the protons on the adjacent carbons. The presence of the hydroxy group was confirmed by mass spectrometry.